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ABSTRACT 
Evaluation of Microencapsulation as an Improved Vaccination 
 Strategy against Brucellosis. (May 2007) 
Angela Maria Arenas Gamboa, D.V.M., La Salle University, Colombia 
Co-Chairs of Advisory Committee: Dr. Allison Rice Ficht 
         Dr. Thomas A. Ficht 
 
 Brucellosis is an important zoonotic disease of nearly worldwide distribution. 
Despite the availability of live vaccine strains for bovine (S19, RB51) and small 
ruminants (Rev 1), these vaccines have several drawbacks including residual virulence 
for animals and humans. Safe and efficacious immunization systems are therefore 
needed to overcome these disadvantages. Brucella melitensis and Brucella abortus 
mutants in the luxR gene were generated and investigated for theri potential use as 
improve vaccine candidates. Immunization with a sustained release vehicle to enhance 
vaccination efficacy was evaluated utilizing the live mutants in encapsulated alginate 
microspheres containing a non-immunogenic eggshell precursor protein of the parasite 
Fasciola hepatica (Vitelline protein B, VpB). BALB/c mice were immunized with either 
encapsulated or nonencapsulated vaccine candidates to evaluate immunogenicity, 
safety and protective efficacy. The results suggest that luxR mutants, are attenuated  in 
the mouse and macrophage model and appear good and safe vaccine candidates when 
the immunogen is given in a microencapsulated format. We were also able to 
demonstrate the utility of microencapsulation in oral delivery by increasing vaccine 
performance of current licensed vaccine strains in a natural host, the Red Deer. 
 iv 
 Together, these results suggest that microencapsulation of live Brucella 
produces an enhanced delivery vaccine system against brucellosis increasing the 
efficacy of poorly-performing nonencapsulated vaccine candidates. 
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INTRODUCTION AND LITERATURE REVIEW 
 
BACKGROUND 
 The organism. Brucella is a gram-negative, facultative intracellular coccobacillus 
that belongs to the alpha-2  subdivision of Proteobacteria. The traditional classification 
of Brucella species is largely based on its preferred hosts: B. melitensis (goats), B. 
abortus (cattle), B. suis (swine), B. canis (dogs), B. ovis (sheep) and B. neotomae 
(desert mice). Two new Brucella species, called Brucella pinnipediae and B. cetaceae, 
have been isolated from marine hosts within the past few years (24, 48). The Brucella 
genome consists of  two circular chromosomes of approximately 2.1 MB and 1.2 MB 
and has a GC content of approximately 57%. The DNA sequences among different 
Brucella spp. share greater than 90% homology (38) 
 Among the six different Brucella species, B. melitensis, B.suis and B. abortus are 
pathogenic and virulent, not only for sheep, goats, swine and cattle, respectively, but 
also for humans. Infection in animals most commonly occurs through ingestion or 
inhalation of contaminated tissues or in many cases may be sexually transmitted (38). 
Typical manifestations of the disease are abortions and infertility. Human brucellosis or 
“Malta Fever” is characterized by the development of undulant fever, osteoarthritis, 
spondylitis and endocarditis (56). Manifestations are usually non-specific including 
lymphadenopathy, hepatomegaly, or splenomegaly. The disease is transmitted to  
 
This dissertation will follow the style of Infection and Immunity. 
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humans by consumption of unpasteurized milk and dairy products or by direct contact 
with infected animals. Airborne transmission of brucellosis has been studied in the 
context of using Brucella as a biologic weapon. In fact, B. suis was the first agent 
contemplated by the U.S. Army as a potential biologic weapon (56). 
  Pathogenesis. The key aspect of Brucella virulence is its ability to proliferate 
within macrophages and non professional phagocytes (18). The bacteria successfully 
bypasses the bactericidal effects of phagocytes and its virulence is thought to be due to 
their ability to avoid the killing mechanisms of the host cells. Typically, Brucella 
intracellular survival relies upon avoiding fusion of its membrane- bound compartment 
with lysosomes, evading bacterial killing (9, 59).  
 Recent research has allowed the identification of genes implicated in Brucella 
virulence. One virulence factor is the VirB system. It consists of a type IV secretion 
system homologous to the one encoded by A. tumefaciens virB and B. pertussis ptl 
genes (51). This system originally identified from attenuated transposon mutants in 
vitro,  is responsible for the injection of toxins into the cytoplasm of infected cells. 
Previous reports using signature tag mutagenesis have demonstrated that virB mutants 
of B. abortus are unable to establish chronic infections in the mouse model (34). The 
exact role of the Brucella VirB system in virulence is still under investigation (8). 
Different studies have shown that virB mutants of both B. abortus and B. melitensis 
have lost their ability to modulate intracellular trafficking. virB mutants cannot transit to 
the replication compartment and are eventually degraded by the cell.  Recent data 
indicates that VjbR, a quorum sensing-related transcriptional regulator controls the 
expression of the virB operon during vegetative growth or during intracellular infection, 
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although the mechanism of action is still unclear, it does hold an important role in VirB 
regulation (17). 
 In addition to the type IV secretion system, bacterial outer membrane components 
especially lipopolysaccharides (LPS) have also been described as virulence factors that 
are important for survival and replication in the host (44). Brucella has two forms, 
smooth and rough. The presence of O-polysaccharide is the basic difference between 
these two forms. In general, rough strains are less virulent than smooth strains. 
Observations includes a decrease survival rate of rough mutants from macrophages 
and rapid clearance from animal models (42, 43, 58). Although it is well accepted that 
rough variants exhibit reduced virulence in the host, the exact role of O antigen 
specifically in intracellular survival remains controversial (58). 
 Brucella vaccines. Due to the serious consequences of the disease, efforts 
have been made to prevent brucellosis through the use of vaccines. The vaccine strain 
that has been most widely used to prevent the disease in cattle is the B. abortus strain 
19 (64). This vaccine is a smooth organism that naturally became attenuated after being 
kept in the laboratory at room temperature for over a year. The disadvantages of this 
immunogen includes, poorly genetically defined, vaccination of pregnant animals can 
result in abortion and interference with serological assays used for the diagnosis of 
brucellosis, all of these factors are totally undesirable effects for human vaccination.  
 Rev. 1 vaccine is a live smooth attenuated B. melitensis strain for use in sheep, 
goats and rams (11).  Although this vaccine is attenuated when compared with field 
strains it retains some virulence and can cause abortion with variable frequency. 
Because it is a smooth organism it induces the production of antibodies that interfere 
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with the diagnosis. 
 More recently, the development of a rifampicin-resistant rough mutant of B. 
abortus  strain 2308 was developed called Strain RB51 (63). Due to its rough 
characteristic, it does not induce O- antibodies being an advantage for Brucella 
diagnosis. However, this vaccine confers less protection than S19, does not protect 
against infection or abortion in wildlife including bison and elk, possesses an antibiotic 
resistant gene and although rarely, it has been associated with infection in humans (7). 
 The use of recombinant antigens or killed vaccines to induce a protective immune 
response to animals has proven ineffective at this time (82). The strategy relies upon 
the identification of those Brucella antigens that are responsible for the induction of a 
protective response, and although some levels of protection have been achieved the 
vaccine efficacy is reduced when compared to the one elicited by the live vaccines (11). 
 Immunity towards Brucella  infections. It is well established that Brucella-
specific IgG levels become elevated during the early stages of infection in animals and 
humans, but there is no correlation between the appearance of these serologic 
responses and resolution of the infection. For Brucella, cellular immunity is understood 
to be critical for resolution of primary infection and for establishment of immunity to 
reinfection (79).        
 Considerable amount of experimental evidence suggests that T cells are the key 
players against brucellosis. The major T cell responses towards Brucella immunity can 
be divided into three principal functions: secretion of IFNγ for the activation of 
bactericidal function in macrophages, cytotoxic T-lymphocyte activity and contribution in  
IgG2a and IgG3 isotype switching (38). It has been clearly demonstrated that a Th1 
5 
 
response is essential for resolution of the primary infection caused by Brucella, and the 
essential aspect of this response appears to be IFNγ production (47). The role of IFNγ in 
the control of Brucella infections was initially demonstrated by supplementing BALB/c 
mice with recombinant IFNγ. The treatment resulted in a 10-fold decrease in the number 
of bacteria at 1 week after infection (68). In accordance with these observations, 
depletion of IFN-γ by the administration of monoclonal antibodies which neutralize IFN-
γ, resulted in the increase in the bacterial burden 1 week post-infection (81). The 
importance of IFNγ in resolution of Brucellosis was recently supported by studies using 
BALB/c and C57BL/6 mice. C57BL/6 mice with gene deletions or disruptions in the 
interferon-gamma (IFN-gamma), perforin or beta(2)-microglobulin, genes had a 
decreased ability to control intracellular infections with B. abortus strain 2308 during the 
first week post-infection. However, only the IFN-gamma knock-out mice had a sustained 
inability to control the infection and this resulted in death of the mice at approximately 6 
weeks post-infection (49). In vitro studies have suggested that the mechanism by which 
IFN-γ enhances resistance is through activation of macrophages for anti-Brucella 
activity, largely by promoting production of reactive oxygen intermediates (36). 
 Different studies have demonstrated a role for both CD4+ or CD8+ T cells in the 
control of brucellosis. Adoptive transfer in BALB/c mice with either CD4+, CD8+ from 
mice immunized for 6 weeks resulted in reduction of bacterial burden in the spleen 
compared to  naive mice after B. abortus infection, suggesting that both T-cell 
populations are important (5). Clear involvement of CD8+ T cells in brucellosis was 
demonstrated in MHC class I and II knockout mice  that  were infected with B. abortus 
S19. MHC class I-deficient mice, which have no CD8+T cells, controlled the infection 
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more slowly than MHC II and wild-type (52). Additional evidence to support the CD8+ T 
cell importance in brucellosis came from experiments where mice were immunized with 
B. abortus conjugated to a peptide derived from the HIV-1 envelope. Following a series 
of immunizations, these mice developed peptide-specific antibodies that neutralized the 
virus. In addition, they developed MHC class I restricted CD8+T cells capable of killing 
target cell expressing HIV(31, 80). Most importantly, mice deficient in CD4+ T cells and 
immunized using the same preparation elicited the same response, suggesting that the 
conjugates were being taken up by DCs that stimulated CD8+ T cells to differentiate into 
memory cells in the absence of CD4+ T cells. A more recent study regarding this aspect 
was performed in BALB/c. Mice were immunized with Escherichia coli expressing 
Brucella abortus Cu/Zn superoxide-dismutase. Animals that received the vaccine, were 
able to elicit protective immunity against B. abortus wild-type challenge and when 
splenocytes were separated into CD4+ and CD8+ populations, CD8+ T cells were able to 
elicit lytic capacities, while CD4+ cells induced IFNγ production (4).   
 Murine brucellosis is not lethal in mice, unless IFNγ effects are eliminated (49). 
Extensive data demonstrates that the CD4+ T cells are the major producer of IFNγ in 
Brucella (82). Experimental evidence obtained from infected CBA mice vaccinated with 
S19 indicated that CD4+ T cell enriched population produced statistically significantly 
higher amounts of IFNγ than CD8+ T cell populations. The strongest evidence to date, 
comes from Araya and Winters. They reported that CD4+T cells  from mice immunized 
intraperitoneally with the vaccine strain RB51, when stimulated with RB51 infected 
macrophages, produced IFNγ in greater amounts than CD8+T cells. The same authors 
also confirmed that CD8+T cells displayed highly significant lysis of macrophages 
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infected with Brucella. However, similarly stimulated CD4+ T cells also were cytotoxic 
suggesting the possibility that CD4+ also may function as cytotoxic cells(79). Previous 
studies have reported that exogenous IL-10 increases and lack of IL-10, reduces 
bacterial burden in BALB/c mice (27). Among T cells, the CD4+ T cell appears to be the 
producer of this cytokine (28). Taking all of these data into account, it appears that CD4+ 
T cells function as effector cells by producing IFNγ, which is beneficial for the control of 
the infection, but their role can be deleterious when secreting IL-10. (79).  
 Limited studies have investigated T cell responses in  species other than mice. 
In humans, diminished percentage of peripheral CD4+ T lymphocytes expressing IL-
2Rα has been associated with chronic relapsing brucellosis(65). In cattle, it is known 
that CD4+ cells proliferate and produce INFγ in a MHC-II restricted fashion, after 
immunization (76). A major difference between ruminants and other species such as 
mice and humans is the large number of γδ T cells. In cattle, limited information 
regarding this aspect is available but the findings suggest that there is proliferation of 
the γδ T cells to Brucella antigens, although relative numbers of all subsets appear to 
remain constant throughout infection (76). 
8 
 
MICROENCAPSULATION AND EVALUATION OF Brucella VACCINE CANDIDATES 
INTRODUCTION         
 The development of safer and more efficacious vaccination strategies to prevent 
Brucellosis is needed to overcome the disadvantages of the currently licensed vaccine 
strains. One of the main conditions for an ideal anti Brucella vaccine is the lack of 
virulence for the target host in order to avoid virulence related sequelae. Recent 
research has focused in the development of such vaccines, however they have proven 
to be less effective in preventing the disease. These strategies include the use of killed 
organisms, cell extracts, or recombinant proteins. In general, vaccination using these 
methods induce lower levels of protection compared to live attenuated Brucella 
vaccines.           
 We hypothesized that in order to generate a good immune response from the 
vaccine, controlled release of live and highly attenuated vaccine strains can be used to 
potentiate their vaccine efficacy.        
 Controlled release. Years of investigation have been focused on a variety of 
both natural and synthetic systems for establishment of a controlled release 
methodology of different products (21, 78). The most widely used microparticle vaccine 
delivery systems used to date are liposomes and poly lactide-co-glycolide 
microcapsules (19, 20). In the case of controlled release formulations, a product is 
typically encapsulated and  released from the capsule by erosion, diffusion or solvent 
activation and transport (46, 72). This process will create the means for a sustained 
release of the product. The desired polymer characteristics include low toxicity, 
biocompatibility, lack of immunogenicity and capacity of breakdown inside the body. 
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Many of the processes used to entrap substances involve the use of harsh conditions 
including organic solvents, shear stress and ultrasound homogenization all of these 
being bactericidal and capable of denaturing proteins (45).    
 Alginate microspheres. Alginate, a naturally occurring biopolymer is especially 
well suited for entrapment of living bacteria mainly due to its characteristics including 
relatively inert aqueous environment within the matrix, a mild room temperature 
encapsulation process free of organic solvents, a high gel porosity which allows for high 
diffusion rates of molecules, an ability to control its porosity with coating procedures, 
dissolution and biodegradation under normal physiological conditions (75). Commercial 
alginates are extracted primarily from three species of brown algae. These include 
Laminaria hyperborea, Ascophyllum nodosum, and Macrocystis pyrifera. Other sources 
include Laminaria japonica, Eclonia maxima, Lesonia negrescens and Sargassum 
species (66). In nature, Alginate is found in the intracellular matrix where it exists as a 
mixed salt of various cations found in sea water such as Mg2+, Ca2+, Sr2+, Ba2+, and Na+. 
The native alginate is mainly present as an insoluble Ca2+ crosslinked gel (75).
 Alginates are a family of linear unbranched polysaccharides which contain 
varying amounts of 1,4′-linked β--mannuronic acid and α--guluronic acid residues. The 
residues may vary widely in composition and sequence and are arranged in a pattern of 
blocks along the chain. The composition and extent of the sequences and the molecular 
weight determine the physical properties of the alginates (75).  
 Alginate microbeads can be prepared by extruding a solution of sodium alginate 
containing the desired material to be encapsulated, as droplets, into a divalent 
crosslinking solution such as Ca2+, Sr2+, or Ba2+. Monovalent cations and Mg2+ ions do 
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not induce gelation. Depending on the divalent solution used such as Ba2+ and Sr2+ ions 
alginate gels can be stronger than Ca2+  crosslinked gels (66). Other divalent cations 
such as Pb2+, Cu2+, Cd2+, Co2+, Ni2+, Zn2+ and Mn2+ can also crosslink alginate gels but 
their use is limited due to their toxicity (75). The gelation and crosslinking of the 
polymers are mainly achieved by the exchange of sodium ions from the guluronic acids 
with the divalent cations (Fig 1). The physical properties of crosslinked alginate 
microspheres are dependent on the composition, sequential structure, and molecular 
size of the polymers.         
 Materials encapsulated in alginate hydrogels are released from the capsule by 
diffusion of the material though the pores of the polymer network and or  by degradation 
of the polymer network (75). Electron microscopic analysis of calcium alginate 
microbeads has shown that the pore size ranges from 5 nm to 200 nm in diameter. 
Diffusion of small molecules such as glucose is unaffected by the alginate matrix while 
diffusion of larger materials from the gels has been shown to be dependent on their 
molecular weight. It has been clearly demonstrated that by increasing the concentration 
of alginate in the beads, the rate of diffusion  of the materials is decreased from the gel 
(75). The gelation and crosslinking of the polymers are mainly achieved by the 
exchange of sodium ions from the guluronic acids with the divalent cations(75). Gels 
made from high α--guluronic acid alginates have the most open pore structure and 
exhibit the highest diffusion rates for encapsulants  which may be related to the lower 
shrinkage of this type of gel or to a difference in the diffusion barrier at the surface of the 
spheres. 
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FIG. 1. Schematic representation of microencapsulation using alginate as the 
polymer. Microbeads can be prepared by extruding a solution of sodium alginate 
containing the desired material to be encapsulated, as droplets, into a divalent 
crosslinking solution such as Ca2+
Alginate + 
material to be 
encapsulated 
is mixed 
Nozzle that has a specific pore 
size, creates droplets of a 
determined size 
Polymerization 
solution. 
(Divalent 
cations) Polymerized capsules 
Stirrer Bar 
(procedure 
performed 
under 
constant 
stirring) 
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 Another aspect that needs further attention for encapsulation  is the charge of 
the material to be entrapped into the alginate bead. It has been demonstrated that the 
charge of the material can influence the diffusion rate from the alginate matrix. A 
protein, microorganism or drug with a potentially net positive charge can interact with 
the negatively charge alginate polymer, inhibiting diffusion from the gel (66). Conversely 
a protein with a low pI or low molecular weight drugs may be released more rapidly from 
the matrix than would be expected from free molecular diffusion (75). The porosity of an 
alginate gel can be reduced significantly by partially drying the microbeads (75). It has 
been shown that spheres made from a high α--guluronic acid alginate will reswell only 
slightly upon rehydration resulting in an increased alginate concentration in the bead 
and a reduced pore size (66). Complete dehydration can result in surface cracking 
which can facilitate the surface erosion of the beads upon rehydration.  
 Reduction in pore size of an alginate matrix can also be achieved by exposing 
the gel to low pH. Release of macromolecules from alginate beads in low pH solutions 
is also significantly reduced which could be advantageous in the development of an oral 
delivery system.        
 Modification of capsule formulation. Several modifications can be performed 
to change the capsule performance in the host. To test further increases in  the efficacy 
of the capsular delivery, a novel recombinant form of the Vitelline protein B (VpB) 
derived from the eggshell precursor of the parasite Fasciola hepatica was incorporated 
into the capsules (61).  VpB possesses an unusual resistance to enzymatic and 
chemical breakdown and this is expected to extend the time frame of erosion and 
release of the capsule content (73).       
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 Vaccine candidates.  Recently, a new technology for in vivo screening of 
virulence genes has been applied in several pathogenic bacteria and fungi. The method 
is described as signature-tagged mutagenesis (STM). STM allows the screening for loss 
of virulence in an animal model of infection (32). STM has identified several Brucella 
genes whose activity contributes to intracellular survival (3, 77). Mutants identified by 
this approach have differences in the degree of attenuation. Mutants exhibiting the 
greatest level of attenuation are the safest for the host and were the focus of this study. 
Among these, we have identified the luxR gene (BMEI1116), encoding the luxR-like 
quorum sensing-related transcriptional regulator that is required for virB expression 
(17). luxR mutants of B. melitensis in initial screenings appeared highly attenuated for 
virulence in macrophage screening, making this mutant ideal vaccine candidates for 
microencapsulation.         
 Using microencapsulation systems we conducted a study  to develop safer and 
more efficacious anti Brucella vaccines. Previous research has shown that the only 
effective vaccines for Brucellosis are live bacteria that stimulate the immune system 
through infection (11). Non desired effects using this approach include abortion  and 
development of arthropathy associated with Brucella antigen-containing immune 
complexes (11, 13). Previous studies had suggested a relationship between persistence 
of the vaccine and its efficacy (37). The use of an attenuated Brucella mutant which is 
not capable of producing these side effects has also the problem of low persistence in 
the host because of the reduced virulence, and such mutants are not capable of 
surviving in the host for the necessary amount of time to develop immunity. By 
encapsulating the organism we studied the possibility of providing the means for an 
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extended exposure time to the host immune system and thereby increase the vaccine 
efficacy. 
MATERIALS AND METHODS 
 Mice.  One hundred and twenty 4 to 6-week old female BALB/c mice were 
obtained from the Jackson Laboratory (Bar Harbor, ME).  All experimental procedures 
and animal care were performed in compliance with institutional animal care 
regulations. 
 Bacterial strains.  Bacteria used in these experiments include B. melitensis 
luxR::Tn5 used as the vaccine candidate and B. melitensis virulent strain 16M.  For 
assessment of bacterial distribution throughout the capsule 16M transformed with the 
pBBR1mcs 6-y plasmid and expressing the reporter protein GFP was kindly provided by 
Dr Marty Roop. Bacteria were grown on tryptic soy agar (TSA) at 37°C with 5% (v/v) 
CO2. For  luxR::Tn5, the medium was supplemented with kanamycin (100µg/ml).  
Following 3 days of incubation, bacteria were harvested from the surface of plates into 
phosphate buffered saline (PBS).  The  bacteria were pelleted, and washed twice by 
resuspension in buffer containing MOPS (10mM MOPS, 0.85% NaCl, pH 7.4), and 
resuspended to a final concentration of 1x106 CFU /ml for encapsulation, or 1x105 
CFU/ml nonencapsulated based upon optical density (OD) readings using a Klett meter 
and a standardized curve.  The actual viable counts were confirmed by serial dilution 
and plating of portions onto TSA plates with or without antibiotic. 
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 Evaluation of B. melitensis luxR::Tn5 in J774A.1 macrophages. Murine 
macrophage-like J774.A1 (ATCC TIB-67) were used to assess luxR::Tn5 mutant 
survival compared to the parental B. melitensis wild-type 16M.  Macrophage survival 
assays were performed as previously described with some modifications (58). Briefly, 
macrophages were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% 
(v/v) fetal bovine serum, 1mM L-glutamine, and 1mM nonessential amino acids.  
Monolayers of macrophages containing 2.5 x105 cells per well were infected at a 
multiplicity of infection of 1:100, at 37°C with either luxR::Tn5 or wild-type 16M.  Thirty 
minutes post infection, cells were washed twice with medium without antibiotics and 
then incubated with 50µg/ml of gentamicin (Invitrogen,USA) for 30 min to kill any 
extracellular bacteria. One and 48 hours post-infection, macrophages were lysed using 
0.05% (v/v) Tween-20, and bacteria collected.  Brucella entry and survival was 
determined by performing serial dilutions and plating onto TSA plates with or without 
antibiotic.  All assays were performed in triplicate and repeated at least three times.  
 Evaluation of B. melitensis luxR::Tn5 attenuation in mice. Female BALB/c 
mice were used to evaluate survival of the luxR::Tn5 mutant.  Briefly, 4-to 6-week-old 
mice were intraperitoneally inoculated with a total of 2x106 CFU of either mutant or wild 
type organism.  Groups of 5 mice were euthanized via carbon dioxide asphyxiation at 
1,2,3 and 4 weeks post inoculation. At each time point, spleens were collected, weighed 
and homogenized in 1ml of peptone saline.  Serial dilutions were prepared, and 100µl 
aliquots of the different dilutions were plated in duplicate onto TSA or TSA/kan. Levels 
of infection were expressed as the mean ± standard error of the mean (SEM) of 
individual log CFU/ spleen.       
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 Preparation of B. melitensis antigen-loaded microspheres.  Alginate beads 
were prepared as previously described with some modifications(1). Briefly, 6x106 CFU 
of the live B. melitensis mutant luxR::Tn5 was re-suspended in 1ml of MOPS buffer 
(10mM MOPS, 0.85% NaCl, pH 7.4) and mixed with 5ml of alginate solution (1.5% 
sodium alginate, 10mM MOPS, 0.85% NaCl, pH 7.3).  Spheres were obtained by 
extruding the suspension through a 200 micron nozzle into a 100mM calcium chloride 
solution and stirred for 15 minutes using the Inotech encapsulator I-50 (Inotech 
Biosystems International, Rockville USA).  After extrusion of the bacteria-alginate 
mixture into the CaCl2, the capsules were washed twice with MOPS for 5 minutes and 
further crosslinked with 0.05% poly-L-lysine (PLL, MW 22,000 Sigma, USA) for 10 
minutes.  Following two successive washes, the beads were stirred in a solution of 
0.03% (w/v) alginate for 5 min to apply a final outer shell and washed twice with MOPS 
before storage at 4°C. 
 In a second formulation, VpB  was added as a component of the alginate core 
(luxR::Tn5/VpBcore) by the addition of 1mg of VpB to the bacteria-alginate suspension 
described above.  Extrusion and capsule formation used the same preparation 
conditions. 
 VpB was alternatively added to the shell of the capsule (luxR::Tn5/VpBshell) as 
a cross-linking agent by the addition of VpB in an equimolar ratio of poly-L-lysine/ VpB 
as the third capsule formulation used. 
 Bacterial viability.  To determine the bacterial content per ml of alginate 
particles,  1 ml  of capsules was removed from the encapsulator prior to permanent 
crosslinking with poly-L-lysine or VpB with poly-L-lysine.  The capsules were allowed to 
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settle and washed twice with MOPS buffer and particles were dissolved using 1 ml of 
depolymerization solution (50 mM Na3-Citrate, 0.45% NaCl 10mM MOPS, pH 7.2) with 
stirring for 10 min.  Bacterial number (CFU/ml) per ml of capsules was determined by 
plating onto TSA plates. 
 Bacterial loading and viability was also assessed after the permanent 
crosslinking with poly-L-Lysine. The capsules were allowed to settle and washed twice 
with MOPS buffer. Particles were treated for 10 min with depolymerization solution to 
dissolve the interior of the capsule. Following the depolymerization treatment 0.02% of 
trypsin (Invitrogen, USA) was added for 2 hours at 37°C to cleave the lysine bonds. 
Bacterial number (CFU/ml) per ml of capsules was determined by plating onto TSA 
plates.         
 Characterization of microspheres. The bacterial distribution throughout the 
capsule, sphere morphology and size were assessed via fluorescence microscopy 
(Nikon, TMS).  Three size determinations were made for each formulation and the mean 
value reported. 
 Determination of kinetics of bacterial clearance from mice vaccinated with 
encapsulated luxR::Tn5 To further understand the kinetics of bacterial release from 
alginate microspheres in vivo, BALB/c mice were vaccinated with either encapsulated or 
nonencapsulated luxR::Tn5 at a dose of 1x105  CFU. Mice were euthanized at several 
time-points, spleens were harvested, weighed and homogenized in 1ml of peptone 
saline. Bacterial suspension was serially diluted and plated onto TSA/kan plates. 
Bacterial release from the beads was indirectly measured by determination of CFU 
encountered in the spleen.   
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 In vitro Bacterial release from the capsules. Bacterial release from the 
capsules was assessed using 1ml of capsules resuspended in 10 mls of peptone 
saline).  The release study was conducted at 4°C for 37 days. At 24hr time intervals, 
1ml peptone saline was removed and plated onto TSA to determine CFU/ml. The buffer 
was replaced completely after the withdrawal of each aliquot. Nonencapsulated bacteria 
was used as a control and subjected to the same procedure. Release profiles were 
expressed in terms of daily release, and plotted versus time.  
 Immunization of mice.  Sixty 4-6 week-old female BALB/c mice were randomly 
distributed into groups of 10 for intraperitoneally (IP) vaccination. Animals were given a 
single dose of microcapsules containing 1x105 CFU of  either (a) encapsulated 
B.melitensis mutant luxR::Tn5 in alginate (luxR::Tn5/alginate),  (b) encapsulated 
luxR::Tn5 in alginate with VpB inside the capsule (luxR::Tn5/VpB core), (c) 
encapsulated luxR::Tn5 in alginate with VpB in the shell of the sphere (luxR::Tn5/VpB 
shell).  Control groups received 1x105 CFU of either (a) nonencapsulated luxR::Tn5,  (b) 
Empty capsules (no bacteria entrapped) or (c) two hundred microliters  of MOPS buffer.  
 Evaluation of Brucella specific antibody.  To determine anti-Brucella-specific 
antibody in sera from inoculated mice, 100µl of blood was taken from each mouse after 
0, 2, 4, 8,10,12,14,18 and 24 weeks post vaccination and used for IgG determination by 
ELISA.  Heat killed and sonicated B. melitensis whole cell antigen was used to coat 96 
well plates (Nunc-Immuno plates) at a concentration of 25µg total protein/well.  
Following overnight incubation at 4°C, plates were washed, blocked with 0.5 ml of 
blocking buffer [0.25% (w/v) BSA] then  incubated  with mouse sera diluted 1:100 in the 
same blocking buffer for 1 hr at room temperature.  Following extensive washing to 
19 
 
remove unbound antibody, rabbit anti-mouse IgG horseradish peroxidase (HRP) 
conjugate  (KPL, USA) was added at a dilution of 1:1000 and incubation continued for 
an additional hour. Following this incubation, the plates were washed again and  HRP 
substrate was added, and incubated for 18 minutes.  The reaction was stopped by 
addition of 50 µl of 0.5M NaOH and the absorbance measured at 450 nm (A450).  All 
assays were performed in triplicate and repeated at least three times. 
 Determination of splenocyte cytokine production.  At selected times post-
vaccination, individual spleens from 5 animals per group were extracted and single cell 
suspensions were obtained by grinding the spleen using glass tissue grinders.  After 
lysis of erythrocytes using red blood cell lysing buffer (8.3 g of NH4Cl in 0.01 M Tris-HCl, 
pH 7.5) the cell suspension was washed in complete RPMI 1640 medium containing 
10% (v/v) fetal bovine serum and 50 µg/ml of gentamycin.  The cell number was 
adjusted and added to 24 well plates at a concentration of to 2.5 x 105 cells/well and 
cultured following the addition of 25 µg/well of Brucella melitensis lysate prepared as 
described above. Cells in control wells received medium alone.  After 72 h post 
incubation at 37°C, 5% (v/v) CO2, culture  supernatants were collected and stored at -
20°C.  A panel of Th1  vs T helper 2 (Th2)  [(Interleukin 2 (IL-2), Interleukin 4 (IL-4), 
Interleukin 12 [IL-12-(p70)] and gamma Interferon (IFNγ)] cytokines was determined in 
triplicate using the Bioplex array system (BIO-RAD, USA) according to the 
manufacturer’s instructions. For each cytokine, eight standards ranging from 2 to 32,000 
pg/ml were performed. 
 Determination of cytokine production In vivo. At 0, 10, 30 weeks post-
vaccination and 2 days post-challenge, the mice animals were bleed and serum was  
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obtained from each individual mouse for cytokine determination. Quantification of IFNγ 
and IL-12p70 was determined by ELISA (Ebioscience, USA) following manufacturer’s 
instructions. For each cytokine, standards ranging from 0.2 to 1000 pg/ml were 
performed. Background levels obtained for t=0 were subtracted from the samples and 
the differences between the encapsulated and nonencapsulated formulations at each 
timepoint were determined by ANOVA. Results are expressed as the mean pg/ml of 
each cytokine. 
 Efficacy of vaccination.  At selected times post vaccination, mice (n=5 per 
group) were challenged IP using 1x105 CFU/mouse of B.melitensis wild-type 16M.  One 
week post challenge, mice were euthanized by CO2 asphyxiation and  spleens were 
removed, weighed and homogenized in 1ml of peptone saline.  Serial dilutions were 
prepared and 100 µl portions were plated onto TSA plates.  In some instances, 200-
1000µl of spleen homogenate was plated to determine organism recovery.  To 
differentiate between vaccine candidate and the challenge strain, each dilution was also 
plated on TSA with kanamycin to identify any residual kanamycin resistant vaccine 
strain present.  Levels of infection were expressed as the mean ± SEM of individual 
log10 CFU/spleen. The efficacy of the vaccine compared to naïve animals was 
determined by subtracting the mean CFU/spleen recovered from mice vaccinated with 
the nonencapsulated or encapsulated (luxR::Tn5/alginate, luxR::Tn5/VpBcore or 
luxR::Tn5/VpB shell) vaccine from the mean CFU/spleen  recovered from naïve non-
vaccinated but challenged mice. The efficacy of the encapsulated vaccine compared to 
the nonencapsulated vaccine was determined by subtracting the mean CFU/spleen 
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recovered from mice vaccinated with the capsules from the mean CFU/spleen 
recovered from mice immunized with the nonencapsulated vaccine.   
 Statistical Procedures. Macrophage infection and survival was expressed as 
the mean log CFU ± SD for each group. Intensity of infection (bacterial clearance and 
efficacy of vaccine) at each time point was expressed as mean log CFU±SEM for each 
group.  Cytokine production in vitro was expressed as mean cytokine concentration ± 
SD for each group of five mice.  The significance of differences between groups was 
determined by analysis of variance (ANOVA).  P values <0.05 were considered 
statistically significant. 
 
RESULTS 
 Verification of attenuation of vaccine candidate in vivo and in vitro.  To 
assess the luxR::Tn5 attenuation, J774A.1 macrophages were infected with the mutant 
and compared to the wild-type B. melitensis 16M.  Using an MOI of 100, the ability of 
the bacteria to enter and replicate within macrophage was evaluated.  Shortly after 
infection (t=0 hours) there was no difference (p> 0.05) between the wild type and 
mutant in the number of bacteria (3-4 per cell) infecting the macrophage (Fig. 2).  In 
contrast, by 48 h post infection there was a 2.5 log difference (p< 0.005) in the number 
of organisms infecting the macrophage (100 per cell for 16M and less than 1 per cell for 
the luxR::Tn5).  These results demonstrate that the luxR::Tn5 mutant has a severely 
limited capacity to replicate within J774A.1 macrophages.  
 To evaluate survival in vivo, BALB/c mice were inoculated intraperitoneally (IP) 
with 2x106 CFU of B. melitensis luxR::Tn5 or the 16M parental wild-type strain. 
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Compared to the wild-type strain 16M, the luxR::Tn5 mutant was significantly reduced at 
all time points between 1.5 and 3.6 logs.  There appears to be a brief period between 
week one (p< 0.001) and two (p> 0.05) during which the organism replicates and the 
numbers of B. melitensis luxR::Tn5 in the spleen increase, but by three weeks post-
inoculation the number of organisms in the spleen exhibits a drastic decline (p< 0.001) 
and drops below the level of detection by four weeks post-infection (p< 0.001) (Fig. 3).  
In addition, disruption of  luxR significantly reduced (p< 0.001) splenomegaly at all time 
points consistent with the reduction in colonization of the spleen (Fig. 4). 
 Evaluation of capsule preparation and formulation using B. melitensis. 
Three different types of capsules were prepared using the same basic alginate 
formulation.  Variations on the formulations include the addition of VpB to the core or to 
the shell of the capsule to slow the degradation of the capsules and the release of the 
organism.  In general, the results revealed that despite the differences in formulations, 
all of the capsules prepared appeared spherical and uniform with a mean diameter of 
300µm.  To characterize the bacterial distribution throughout the capsule, B. melitensis 
16M transformed with a GFP expressing plasmid was encapsulated.  The results shown 
in figure 5 reveal uniform bacterial distribution throughout the capsule.  Furthermore, 
bacterial viability following encapsulation exceeded 95% as demonstrated by recovery 
of the organism following dissolution of the capsules (Fig. 6). 
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FIG. 2. Survival of the B. melitensis luxR::Tn5 mutant in J774A.1 macrophages. 
Wild-type strain 16M and the B. melitensis mutant luxR::Tn5 were used to infect 
J774A.1 macrophages at a multiplicity of infection of 1:100. After 30 min of incubation 
followed by 1 hr of treatment with gentamycin, infected macrophages were further 
incubated for 0 or 48h. Treated cells were lysed, serially diluted and plated on TSA or 
TSA/kanamycin plates for CFU determination. Values are the mean of three 
independent  experiments ± standard deviation. Differences in macrophage colonization 
by wild-type 16M and luxR::Tn5 are indicated  (**P<0.005)  
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FIG. 3. Kinetics of clearance of B. melitensis luxR::Tn5 after infection.  BALB/c 
mice (n=5/ time point) were infected with 2 x106 CFU/mouse of wild-type 16M or 
luxR::Tn5. At  1,2,3 and 4 weeks post-infection, mice were euthanized and the spleens 
were assessed for bacterial colonization. Values are the means of individual mice ± 
standard error of the mean. Differences in colonization were determined by ANOVA 
comparing the wild-type to the mutant (**P<0.005). The solid line represents the limit of 
detection which is ≥5 CFU. 
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FIG. 4. Spleen weights after B. melitensis luxR::Tn5 infection. BALB/c mice were 
infected with 2 x106 CFU/mouse of wild-type 16M or luxR::Tn5. At 1,2,3 and 4 weeks 
post-infection, mice were euthanized and the spleens were weighed to determine the 
degree of inflammation conferred by the mutant. Results are expressed as the mean ± 
standard error of the mean. Differences in weight were determined by ANOVA 
comparing the wild-type to the mutant (*P<0.05) (**P<0.005). 
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FIG. 5.  Fluorescent microscopy image of alginate microspheres loaded with 
wild-type 16M. B. melitensis wild-type 16M was fused with a GFP plasmid and further 
encapsulated into alginate microspheres. A uniform bacterial distribution was observed 
throughout the capsule. Microsphere size was measured indicating an average mean 
size of 300µm. 
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FIG. 6. Total CFU recovered after the encapsulation procedure. Wild-type 16M was 
encapsulated into alginate microspheres at a concentration of 2x104 CFU/ml. 
Immediately after encapsulation 1ml of capsules was treated with a depolymerization 
solution followed by an enzymatic treatment that dissolved the beads. Total CFU 
recovery was determined by plating the recovered bacterial suspension onto TSA 
plates. 
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 As an indirect method of measurement of the release of the capsule content in 
vivo, mice were inoculated with either encapsulated or nonencapsulated vaccine at the 
same doses and euthanized at selected time-points described in materials and 
methods. Spleens were homogenized and plated to determine the number of CFU. 
Surprisingly, the mutant luxR::Tn5 did not persist in the tissue for a prolonged period of 
time as predicted, by four weeks the mutant was cleared as observed with the 
nonencapsulated  vaccine (Fig. 7). Results in vitro demonstrated that capsules were 
completely dissolved and bacteria released from the capsules by 36 days of treatment 
(maintained in peptone saline) (Fig. 8).   
 In order to determine the effect of encapsulation on immunization, the level of 
protection provided by equal numbers of encapsulated and nonencapsulated 
B. melitensis luxR::Tn5 was evaluated against wild-type challenge at 31 weeks post 
vaccination.  At this time point, nonspecific activation due to innate immune response to 
persistent infection or delayed release of the encapsulated organism had passed based 
upon the decrease observed in humoral immunity and the absence of recovery of the 
vaccine strain (Fig 9).  At 32 weeks post-vaccination (one week after challenge), all 
mice including the nonencapsulated group had a statistically significant decrease in 
bacterial load in the spleen relative to naïve mice with a 3.14 log reduction (p< 0.05) for 
nonencapsulated mutant, 4.14 log reduction (p< 0.005) for BM luxR::Tn5 in alginate, a 
4.45 log reduction (p< 0.001) for BM luxR::Tn5 in VpB core, and a 4.98 log reduction 
(p< 0.001) for BM luxR::Tn5 in VpB shell compared to MOPS vaccinated mice. All 
groups of mice receiving encapsulated vaccination exhibited a statistically significant 
degree of protection against infection compared to the non-encapsulated mutant  
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FIG. 7. Kinetics of clearance of encapsulated B. melitensis luxR::Tn5 after 
infection.  BALB/c mice (n=5/ time point) were infected with 2 x106 CFU/mouse of 
encapsulated  or nonencapsulated luxR::Tn5. At  1,2,3 and 4 weeks post-infection, mice 
were euthanized and the spleens were assessed for bacterial colonization. Values are 
the means of individual mice ± standard error of the mean. Differences in colonization 
were determined by ANOVA comparing the nonencapsulated to the encapsulated 
vaccine (**P<0.005). The solid line represents the limit of detection which is ≥5 CFU. 
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FIG. 8. Kinetics of bacterial release in vitro from alginate microcapsules. Alginate 
microbeads were prepared containing 1x109  CFU/ml of luxR::Tn5 and 1ml of capsules 
was resuspended in peptone saline and stored at 4°C for the duration of the 
experiment. Every day, buffer was completely removed and new peptone saline was 
added. 100µl aliquots of the buffer was serially diluted and plated onto TSA/kan plates 
to determine the number of bacteria released into the buffer. The solid line represents 
the limit of detection which is ≥5 CFU. 
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 FIG. 9. IgG anti-Brucella antibodies in serum from mice immunized with 
luxR::Tn5. BALB/c mice (n=10) were inoculated IP with 1x 105  CFU of either 
nonencapsulated B. melitensis luxR::Tn5, encapsulated B. melitensis 
(luxR::Tn5/alginate), encapsulated B. melitensis luxR::Tn5 with VpB  in the core 
(luxR::Tn5/alginate/VpBcore)  or encapsulated B. melitensis luxR::Tn5 with VpB in the 
shell (luxR::Tn5/alginate/VpBshell). Control groups received empty capsules or MOPS. 
At 0,2,4,8,10,12,14,18 and 24 weeks post vaccination, serum samples were collected 
and used for IgG determination by ELISA. Results are shown as the mean ± standard 
deviations of absorbance at  A450.  
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(p<0.001). Among the three encapsulated vaccines, the BM luxR::Tn5 in VpB shell 
provided the best level of protection, increasing the vaccine efficacy by 1.84 logs 
(p<0.05) compared to the nonencapsulated vaccine.  Moreover, the challenge organism 
was undetectable from 60% of the mice, which appeared to exhibit sterile immunity (Fig 
10). 
 Encapsulated BM luxR::Tn5 elicits vigorous humoral and cellular immune 
responses.  Serum collected at 0, 1, 2, 8,10,12,14,18 and 24 weeks post vaccination 
was assayed for the presence of Brucella-specific antibodies by ELISA.  Immunization 
with BM luxR::Tn5 elicited a IgG response that was clearly detectable after 2 weeks 
post-vaccination for either encapsulated or nonencapsulated vaccines (Fig. 9).  
However, the three capsule formulations elicited similar IgG responses, but over a 
prolonged period compared with the nonencapsulated vaccine.  In mice vaccinated with 
the nonencapsulated BM luxR::Tn5 vaccine, IgG levels peaked at 8 weeks post-
immunization, while BM luxR::Tn5 in VpB shell IgG levels increased steadily and 
reached a maximum after 18 weeks post immunization (p>0.05).  In this case, an 
induction of higher and sustained antibody levels coincides with increased protection for 
both BM luxR::Tn5 in alginate and luxR::Tn5 in VpB core formulations. 
 To obtain additional information on the type of immune response induced by the 
different BM luxR:Tn5 capsule formulations at the time of bacterial challenge, the 
cellular immune response was characterized based on cytokine secretion in culture 
supernatants of spleen cells from immunized mice.  All three capsule formulations 
stimulated elevated levels of IFNγ (p< 0.005), IL-12p/70 (p< 0.05), GM-CSF (p< 0.001) 
(Fig. 11A-C) compared to the nonencapsulated group and only capsules with VpB in the  
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FIG. 10. Immunization efficacy of B. melitensis luxR::Tn5 vaccine formulations. BALB/c mice were immunized i.p.  
with 1x 105  of either nonencapsulated B. melitensis luxR::Tn5, encapsulated B. melitensis luxR::Tn5/alginate, 
encapsulated B. melitensis luxR::Tn5 with VpB  in the core (luxR::Tn5/alginate/VpBcore)  or encapsulated B. melitensis 
luxR::Tn5 with VpB in the shell (luxR::Tn5/alginate/VpBshell). Control groups received empty capsules or MOPS. After 
31 weeks, mice were challenged i.p.  with 1 x 105  CFU wild-type 16M. One week post challenge, mice were euthanized, 
spleens harvested and the bacterial load was determined. Values are reported as the log10 recovery of 16M from 
spleens, with individual mice in each treatment group represented. The solid line represents the limit of detection which is 
≥5 CFU. Differences in colonization between the nonencapsulated and encapsulated groups was determined by ANOVA 
(*P<0.05) (**P<0.005). 
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formulation stimulated higher IL-2 (p< 0.005) production compared to the 
nonencapsulated vaccine (Fig. 11D).  All cytokine levels were statistically significant 
compared to naïve non-vaccinated animals (p< 0.005).  In general, induction of higher 
Th1 cytokine levels coincided with the elevated protection exhibited in the encapsulated 
vaccine groups.  Spleen cells from all immunized mice failed to produce IL-4 when 
stimulated with antigen (Fig. 11E).  No statistical significance was observed either 
between the vaccinated and non-vaccinated animals, or between encapsulated and 
nonencapsulated formulations with this cytokine. Empty capsules failed to elicit 
production of any of the cytokines measured. 
 To correlate cytokine expression in vivo, animals were bleed at 0, 10, 30 weeks 
and 2 days post-vaccination to determine IFNγ and IL12 concentrations in serum. 
Interestingly, results correlated with the observations obtained in vitro. Animals 
receiving the encapsulated vaccine were able to elicit higher levels of IFNγ at all 
timepoints in mice vaccinated with either alginate/luxR::Tn5 or alginate/luxR::Tn5/VpB 
shell (p< 0.05) (Fig. 12A). IL-12 was only significant at 10 and 30 weeks post-
vaccination in animals vaccinated with alginate/luxR::Tn5 (P< 0.005, P< 0.05, 
respectively) and at 10 weeks in animals that received the other two capsule 
formulations (P <0.05) (Fig 12B). 
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FIG. 11. Production of cytokines in stimulated spleen cells from luxR::Tn5 vaccinated BALB/c mice. 
Mice were vaccinated with 1 x 105 CFU of either nonencapsulated B. melitensis luxR::Tn5, encapsulated 
B.melitensis luxR::Tn5/alginate, encapsulated B. melitensis luxR::Tn5 with VpB  in the core 
(luxR::Tn5/alginate/VpBcore)  or encapsulated B. melitensis luxR::Tn5 with VpB in the shell 
(luxR::Tn5/alginate/VpBshell). Control groups received empty capsules or MOPS. Thirty one weeks post 
vaccination, mice were euthanized, splenocytes harvested and stimulated  with heat inactivated B. 
melitensis 16M or  medium alone as a control. IFNγ (A), IL-12p70 (B), GM-CSF (C), IL-2 (D) and IL-4 (E) 
production (pg/ml) were detected after 72 h of stimulation using a multiplex suspension array system 
(Bioplex). Cytokine production  was expressed as mean cytokine concentration ± SD for each group of five 
mice.  The significance of differences between nonencapsulated and encapsulated formulations was 
determined by ANOVA. (*P<0.05), (**P<0.005).  
 
 
 
36 
 
 
 
 
FIG. 11 (continued) 
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FIG 11. (Continued) 
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FIG. 12. Cytokine production in BALB/c mice immunized with luxR::Tn5. Mice 
were vaccinated with 1 x 105 CFU of either nonencapsulated B. melitensis luxR::Tn5, 
encapsulated B.melitensis luxR::Tn5/alginate, encapsulated B. melitensis luxR::Tn5 
with VpB  in the core (luxR::Tn5/alginate/VpBcore)  or encapsulated B. melitensis 
luxR::Tn5 with VpB in the shell (luxR::Tn5/alginate/VpBshell). Control groups received 
empty capsules or MOPS. Mice were bled at 0,10,30 weeks post-vaccination and 2 
days post-challenge and IFNγ (A) or IL-12 (B) determination from the serum was 
performed by ELISA. Results are represented as the mean cytokine concentration ± 
SEM for each group of ten mice.  The significance of differences between 
nonencapsulated and encapsulated formulations at each timepoint was determined by 
ANOVA. (*P<0.05), (**P<0.005). 
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FIG. 12 (Continued) 
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DISCUSSION 
 Efficacious immunization systems to protect against brucellosis are needed to 
overcome the disadvantages of the currently available vaccines with regard to efficacy 
in a wide variety of hosts.  Second only to immune protection, safety is of critical 
importance for ideal live Brucella  vaccines.  The absence of virulence in the target host 
and in humans will help to avoid virulence related sequellae.  Increasing knowledge of 
virulence factors and Brucella  pathogenesis mechanisms provide us with the tools to 
construct new attenuated strains.  Previous studies in our lab  have identified genes 
related to survival and virulence using transposon-based mutagenesis strategies (77).  
Among the genes identified, luxR::Tn5 mutants were evaluated for survival in 
macrophages and the mouse model to confirm attenuation and immune potential.  As 
shown in this study, BM luxR::Tn5 was  defective for survival within macrophages, and 
rapidly cleared from the spleen in BALB/c mice.  In mice, the mutant was significantly 
reduced in number by 1 week post infection and was completely cleared by 4 weeks;  in 
contrast, 16M clearance from the spleen takes more than 16 weeks (37). luxR::Tn5 
safety was further revealed by the absence of splenomegaly in inoculated mice.  Even 
at 2 weeks, when the bacterial load in the spleen was high, the mean spleen weights in 
BM luxR::Tn5 inoculated mice was 110 mg vs. 653 mg for 16M (Fig. 4).  In contrast, 
currently available vaccine strains S19 and Rev-1 induce splenomegaly in mice (67).  
Differences in survival and inflammatory response exhibited by luxR::Tn5 provide an 
opportunity to evaluate its use as an improved vaccine candidate. 
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 Recent reports demonstrate that persistence of the vaccine strain in the host is 
needed for the development of a suitable and long term immunity (37).  Consistent with 
this, currently used protective strains exhibit only modest attenuation, meaning they 
survive longer in the host and produce unwanted side effects (67).  To overcome this 
problem, we developed a controlled release strategy using highly attenuated mutants to 
increase the exposure of host  to the organism.  Alginate-VpB microspheres permit a 
constant or pulsed release of encapsulated organism, simulating continuous exposure, 
that potentiates vaccine efficacy. Release from alginate matrices generally occurs by 
diffusion through pores of the capsule or by erosion of the polymer network.  In the case 
of standard bacterial entrapment methods used for Mycobacterium bovis BCG or 
bifidobacteria, cells escape through erosion rather than diffusion due to  bacterial size 
and surface charge (2, 14). VpB was added to the formulation, in an attempt to extend 
the time frame over which the capsule dissolution occurs, due to the characteristic 
resistance of the protein to enzymatic breakdown.   
 During microsphere formulation microorganisms were exposed to relatively mild 
conditions that did not cause significant bacterial death; this approach permits the 
development of live encapsulated vaccines in contrast to previously published 
encapsulation procedures in which the viability of the bacteria is compromised due to 
the extreme conditions including ultrasound homogenization, direct exposure to organic 
solvents and shear stress (45).  The use of GFP plasmid transformed organism helped 
to confirm bacterial viability and distribution inside the capsules and demonstrated 
uniform spherical capsule formation. This morphology was maintained even with the 
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inclusion of VpB, which enhances capsule stability via crosslinking due to its high lysine 
and arginine content when substituted for poly-L-lysine (61, 73). 
 Protection studies against wild-type challenge with both nonencapsulated and 
encapsulated organisms protected mice significantly, but the vaccine efficacy was 
increased substantially when the mutant was delivered in an encapsulated form.  
Addition of VpB in the core or shell of the capsule further enhanced protection , 
corroborating the observation of protection as a function of vaccine persistence.  
Encapsulation and incorporation of VpB in vaccine formulations is an interesting 
approach to improve immunization efficacy not only for Brucella, but potentially for other 
organisms as well. 
 The degree of protection conferred by the different vaccine formulations was 
compared to the humoral profiles.  Immunization with B. melitensis luxR::Tn5 in 
microcapsules induced prolonged elevation of IgG levels when compared with the 
nonencapsulated vaccine.  Persistent levels of IgG even at 18 weeks post-vaccination 
might reflect the extended exposure time of the host to the organism.  In the case of 
 luxR::Tn5/alginate/VpB core we were able to correlate elevated and persistent levels at 
late time points post-vaccination with a sterile immunity provided by the vaccine in 3 of 5 
animals.  
 Published reports have shown that spleen cells from mice previously inoculated 
with live vaccines induced a Th1  type response to Brucella antigens in vitro, while 
splenocytes from mice immunized with killed vaccines induced Th2  responses (82). 
Moreover, it has been clearly established that IFNγ is an important component of the 
Th1 response, activating macrophages for increased microbial killing.  Studies 
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performed with this mutant indicate that both luxR::Tn5 and encapsulated luxR::Tn5 
induced higher IFNγ levels relative to naïve mice, but the levels of IFNγ induced by the 
nonencapsulated vaccine were lower compared to the three capsule formulations. 
Higher cytokine concentrations coincided with the increased levels of protection 
generated by the capsule formulations.  
 Although IFNγ is critical for activating macrophages, other cytokines also play an 
important role in controlling Brucella.  IL-12, a Th-1 type cytokine mainly produced by 
macrophages, promotes IFNγ production by T cells that induce murine B cells to switch 
to IgG2a isotype (29). It also induces differentiation of CD4 Th1 cells. This data was 
also correlated with the results obtained from the serum at the different timepoints post-
immunization. In our vaccination trials, IL-12  was also produced in significant levels 
compared to naïve mice.  Two of the three groups of animals that received 
microcapsules (luxR::Tn5/alginate and luxR::Tn5/alginate/VpBcore) produced higher 
statistically significant levels compared to the nonencapsulated vaccine suggesting that 
IL-12 has also a protective role. An alternative explanation could be that the higher IgG 
levels in serum produced by the capsule formulations might be caused by the elevated 
IL-12  concentrations observed here. Further analysis to determine which type of IgG is 
being produced should be assessed in order to correlate  IgG2a antibody production 
with an IL-12 response.  
 Finally, IL-2 was also analyzed. The only formulation that had a significant 
difference compared to the nonencapsulated vaccine was the luxR::Tn5/vpBcore. It has 
been previously demonstrated that IL-2 not only promotes secretion of Natural Killer 
cells (NK) derived cytokines such as GM-CSF and INFγ but is also diminished in 
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patients with chronic brucellosis (65). In this case, presence of high levels of this 
cytokine might be a reflection of an improved memory response with subsequent 
protection against wild-type challenge. The levels of GM-CSF observed in spleen 
supernatants could also be explained by the high IL-2 levels exhibited here.  
 Cytokines described above are all associated with a  Th1 response. Significant 
quantities of Th2-type cytokines such as IL-4 were not detected in these studies.  It is 
important to mention that the microcapsule by itself is not sufficient to provoke the 
secretion of cytokines in culture supernatants.  Statistically significant concentrations of 
any cytokine were not detected in mice vaccinated with empty capsules, suggesting that 
the booster effect generated by the three capsule formulations was due to a continuous 
presentation of antigen  to the host cells. Investigation to further define the basis for this 
response are under way.  
 In this study, mice were vaccinated with a single dose of an attenuated Brucella 
mutant for 31 weeks. Previous studies have not analyzed vaccine candidate 
performance at such late time points. We chose the 6 month time point for two reasons, 
to rule out the action of the innate immunity due to presence of the mutant (because of 
the pulsatile release of the mutant from the capsule) and also to  better assess the 
quality of the memory response generated by the different vaccine formulations 
delivered as a single dose.  
 In summary, our findings indicate that encapsulation of live Brucella 
demonstrates enhancement of  vaccine efficacy. The luxR::Tn5 mutant is a suitable 
vaccine candidate that needs further investigation based on   its reduced virulence in 
macrophages and BALB/c mice and ability to generate protection in the mouse model. 
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We were able to demonstrate a specific Th1 response that did improve when the 
vaccine was given using a controlled release vehicle. Further studies are planned to 
generate an unmarked knockout of the gene to avoid the use of vaccine strains with 
antibiotic resistance genes in the field, and to rule out the possibility of a polar effect due 
to the transposon insertion.  
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EVALUATION OF MICROENCAPSULATED RB51 VACCINE AGAINST 
REINFECTION IN A NATURAL HOST: THE RED DEER MODEL 
 
INTRODUCTION 
Brucellosis eradication programs in North America have been successful in 
controlling the pathogen in domestic livestock, but not in wildlife populations (60).  
Currently, elk (Cervus elaphus nelsoni) and bison (Bison bison) are the wildlife species 
that remain problematic in the Greater Yellowstone Area (GYA).  Within the past few 
years, a big concern has been B. abortus persistence and spread in wildlife reservoirs 
and the threat of disease to cattle (70). 
The increasing prevalence of brucellosis can be mainly attributed to the lack of 
highly effective vaccines for wildlife species.  Commercially available vaccine strains 
used for eradication of brucellosis in cattle have been studied for use in different wildlife 
species (15).  Currently, all vaccination trials have revealed reduced vaccine efficacy in 
elk compared with cattle and several associated drawbacks including interference with 
diagnosis (64), resistance to antibiotics and residual virulence for animals and humans 
do not favor extensive use (6, 7).  B. abortus S19 vaccine strain appears to be safe for 
use in adult elk, but has been shown to reduce abortion rates by only 30% (Thorne et 
al., 1981).  Biosafety results in other species including pronghorn antelope (Antilocapra 
americana) (22), bison (Bison bison) (16) and coyotes (Canis latrans) indicates that the 
vaccine does not cause morbidity or mortality, thus favoring its use to protect elk.  The 
other currently used vaccine strain RB51, has been shown to be safe in a wider range 
of non-target species including ravens (Corvus corax), Richardson ground squirrels 
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(Spermophilus richardsonii), deer mice (Peromyscus maniculatus) (35), bighorn sheep 
(Ovis canadensis), pronghorn (Antilocapra americana), mule deer (Odocoileus 
hemionus), moose (Alces alces shirasi) (40), black bears (Ursus americanus) (55).  
However, when RB51 vaccine is administered parenterally  it does not protect against  
abortion in elk (39) (12).  
The distribution of the disease appears to correlate with elevated animal 
densities associated with winter feeding (23).  Enhancing the probability of 
transmission, Infected and susceptible elk gather on feed grounds assuring exposure of 
a great number of animals to B. abortus.  Control of brucellosis should focus on these 
sites to prevent or reduce the transmission of the pathogen from infected animals.  
Difficulties with Brucella vaccines arise not only because of the reduced efficacy of 
vaccine strains (S19 and RB51), but also resulting from the delivery method used to 
immunize the animals.  Currently, elk vaccination utilizes biobullets of S19 to ballistically 
vaccinate animals from distances of 30 meters (53).  Although this represents an 
improvement over methods requiring rounding up the animals, problems associated 
with this methodology include excessive time, labor, logistics and elevated cost. 
In failure of currently available vaccines to provide safe and efficacious immunity 
in elk, suggests the need for a different approach to vaccinate wildlife. As one 
alternative, we have investigated the ability to combine the use of live attenuated 
vaccines delivered via a controlled microencapsulated release vehicle.  For this 
purpose, alginate a naturally occurring biopolymer offers several advantages including 
biocompatibility, low toxicity and relatively mild conditions required to encapsulate live 
organisms (75).  In an attempt to enhance the efficacy of the capsule, we have also 
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incorporated a novel protein from the eggshell precursor of the parasite Fasciola 
hepatica, Vitelline protein B (VpB) a recombinant protein of 31KDa, which possess an 
unusual enzymatic resistance of the protein to breakdown (61) that could extend the 
time frame of erosion and release of the capsule content.  Oral delivery of 
microencapsulated vaccine was also investigated, since this represents the most cost-
effective way to deliver a vaccine in wildlife populations. 
 
MATERIALS AND METHODS 
 Animals. Fifty four, 1- to 2- year- old Red Deer (Cervus elaphus elaphus) 
females were bought from a privately owned tuberculosis and brucellosis commercial 
free herd as an animal model for Rocky Mountain elk (Cervus elaphus nelsoni) due to 
their close genetic relationship, ease of handling and animal husbandry.  Upon arrival, 
animals were re-tested for anti Brucella IgG levels (total IgG) by ELISA, dewormed  
using Moxidectin and Cydectin and allowed to acclimate for 3 months.  For experimental 
purposes Red Deer were randomly assigned into 6 different treatment groups (n=9).  All 
animal care and experimental procedures were performed in compliance with 
institutional animal care and guidelines. 
 Bacterial strains. Bacterial strains used in these experiments include the 
B. abortus vaccine strains RB51 and S19.  Brucella  was grown on tryptic soy agar 
(TSA) plates incubated at 37°C in atmosphere containing 5% (w/v) CO2 for 72 hours.  
Bacteria were harvested from the plates by scraping them off the plate surface into 
phosphate buffered saline (PBS).  The harvested bacteria were pelleted by 
centrifugation at 3000 x g and the pellet resuspended in fresh PBS.  This step was 
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repeated two more times and the concentration of bacteria determined by optical 
density using a standardized curve of optical density (Klett units) vs. colony forming 
units (CFU).  The concentration of viable organisms was verified retrospectively by 
plating serial dilutions of cell suspensions.  
 Preparation of B. abortus RB51-loaded microspheres. Alginate beads 
loaded with 1.5x1010 CFU/ml of the vaccine strain RB51 were prepared as previously 
described for live bacteria (1) with several modifications.  Briefly, enumerated live RB51 
vaccine strain (total 1.5x1011 for 10 doses) was re-suspended in a total of 100µl of 
MOPS (3-[N-Morpholino] propanesulfonic acid) buffer (10mM MOPS, 0.85% NaCl, pH 
7.4) and mixed with 10 mls of alginate solution (1.5% sodium alginate, 10mM MOPS, 
0.85% NaCl, pH 7.3).  Three hundred µm spheres were obtained by extruding the 
suspension through a 200 micron nozzle into a 100mM calcium chloride solution and 
stirred for 15 minutes using the Inotech encapsulator I-50 (Inotech Biosystems 
International, Rockville USA).  In order to permanently crosslink the capsule, the 
spheres were resuspended in MOPS buffer supplemented with 0.05% (w/v) poly-L-
lysine (PLL, MW 22,000) for 15 minutes.  Following two successive washes, a final 
outer coat was applied to the beads (0.03% (w/v) alginate for 5 min). All capsules were 
stored at 4°C in MOPS buffer until use.  To determine the number of bacteria per 1ml of 
capsule suspension (or one ml of sedimented capsules), spheres were removed from 
the encapsulator prior to permanent crosslinking, washed three times with 50 mls of 
MOPS buffer and were dissolved using 10ml of depolymerization solution (50 mM Na3 – 
citrate, 0.45% NaCl 10mM MOPS, pH 7.2).  Enumeration of bacteria was determined by 
plating serial dilutions onto TSA plates.  
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The addition of VpB as a component of the alginate core was achieved by the 
supplementing the mixtures described above with 1 mg of VpB to the bacteria-alginate 
suspension. Extrusion and capsule formation was performed exactly as described 
above. 
 Immunization of Red Deer. Fifty four 1-2 year-old female Red Deer were 
randomly distributed into 6 different treatment groups (n=9).  Three groups were 
inoculated subcutaneously with a total dose of 1.5x1010 CFU of either nonencapsulated 
RB51, encapsulated RB51 with alginate or encapsulated RB51 with alginate and VpB.  
One group was vaccinated orally with 1.5x1010 CFU of alginate encapsulated RB51 and 
another group with RB51 encapsulated with alginate and VpB.  A control group received 
a subcutaneous injection of 1 ml of empty capsules (no bacteria entrapped).  A single 
vaccination dose was given to each animal in all groups.  
 Detection of Brucella-specific antibody levels. To determine the level of anti-
Brucella-specific antibody in serum, blood samples were collected by jugular 
venipuncture immediately prior to vaccination, and 6, 12, 17 and 28 weeks post-
vaccination. Serum samples were evaluated for total IgG determination by ELISA.  Heat 
killed B. abortus RB51 was used as antigen to coat 96 well plates (Nunc-Immuno 
plates, high binding protein) at a concentration of 25µg/well.  After overnight incubation 
at 4°C, plates were washed with PBS containing 0.05% (w/v) Tween-20, and blocked in 
the same solution supplemented with 0.25% (w/v) BSA to prevent non-specific binding.  
The blocking buffer was removed and deer serum samples diluted 1:100 in blocking 
buffer were incubated for 2 hrs at room temperature with rocking.  Following three more 
washes, horseradish peroxidase conjugated goat anti-deer IgG (KPL, USA) was added 
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to the wells at a dilution 1:1000 and incubated at room temperature for 1 hr.  After 
incubation, plates were washed as describe above and the peroxidase substrate o-
phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich, USA) was added following 
manufacturer’s instructions and incubated for no more than 20 min.  The reaction was 
stopped by the addition of 50µl of 0.5M NaOH and the absorbance measured at 450nm 
(A450).  All assays were performed in triplicate and repeated at least two times.  
 Lymphocyte proliferation Assay from peripheral blood mononuclear cells. 
At 12 weeks post-vaccination, mononuclear cells were isolated from the buffy coats of 
peripheral blood as previously described with some modifications (74).  Briefly, 2 x 105 
cells/well were seeded in 96 well plates (Falcon, Becton Dickinson, USA) in RPMI 
medium containing 10% (v/v) fetal bovine serum, 1mM L-glutamine, and 1mM non-
essential amino acids.  Cells were stimulated with either B. abortus S2308 (wild-type) 
lysate at a concentration of 12.5µg/ml, Concanavalin A (5µg/ml) or medium alone during 
incubation for 6 days at 37°C in atmosphere containing 5% (v/v) CO2 . Following 
incubation, 1µCi of methyl-[3H] thymine was added to each well and incubation was 
continued for an additional 18 hours.  The cells were harvested onto glass fiber filters 
using a 96 well plate cell harvester and the incorporated [3H]thymine was determined 
using a Beckman liquid Scintillation counter.  Data is represented as mean counts per 
minute (CPM) ± standard deviation. 
 Host response against infection by intraocular S19 exposure. Seven 
months post- vaccination three- to four animals from each vaccination group (except 
RB51/alginate SC n=2) were exposed intraocullary as previously described (41) using a 
challenge dose of 1 x 109  CFU/deer of B. abortus strain S19  as confirmed by plating 
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serial dilutions onto TSA plates.  Two weeks post-challenge, animals were euthanized 
and spleens harvested, weighed and homogenized in 1 ml of peptone saline per gram 
of tissue for 5-10 minutes using a stomacher.  One hundred microliter portions of each 
sample were serially diluted and plated in duplicate onto Farrell’s media.  Three to five 
days post-inoculation bacterial counts were enumerated.  Results are represented as 
the mean CFU per gram of tissue ± SEM.  
 Statistical procedures. IgG levels elicited by vaccination are expressed as the 
mean A450±SD for each group.  For blastogenesis, counts per minute (CPM) from each 
group are expressed as the mean CPM±SD.  Intensity of infection from S19 infection 
was expressed as mean log CFU±SEM for each group.  The significance of differences 
between groups was determined by analysis of variance (ANOVA) using Prism software 
(GraphPad).  A P value <0.05 is considered statistically significant. 
 
RESULTS 
 Encapsulation of B. abortus RB51 in alginate microspheres. Two different 
capsule formulations were prepared using the same basic alginate formulation.  
Variation on the formulation included the addition of VpB to the capsule core to modify 
degradation kinetics and release of the organism.  When capsules were analyzed using 
light microscopy, all of the capsules formulations appeared spherical and uniform with a 
mean diameter of 310µm (Fig. 13).  Furthermore, bacterial viability following 
encapsulation exceeded 95% as demonstrated by recovery of the organism following 
dissolution of the capsules (data not shown). 
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 Encapsulated RB51 enhances humoral immune responses.  Serum 
collected at different times post-vaccination was assayed for the presence of Brucella-
specific antibodies by ELISA.  Immunization with RB51 elicited an IgG response in oral 
and SC-vaccinates that was significantly different from naïve animals by 6 weeks post-
vaccination (Fig. 14).  Over the first 17 weeks, IgG levels were consistently higher in 
animals that received the injected vaccine compared to the groups that were immunized 
orally (p <0.05).  Between 17 to 28 weeks, IgG levels in animals that were vaccinated 
orally had an increase in the IgG compared to deer vaccinated via SC (p <0.05).  
 Encapsulated RB51 enhances cellular immune responses. To determine the 
possible effect of encapsulation in the cellular response elicited in Red Deer, a cellular 
proliferation assay was performed.  Animals were bled twelve weeks post-vaccination, 
and blastogenesis was performed using cells isolated from the buffy coat.  Stimulation 
was performed in vitro as described in the materials and methods section and only 
animals receiving the encapsulated vaccine in which VpB was added to the core 
formulation exhibited statistically significant proliferative responses (P<0.0005 oral 
vaccinates, P<0.005 SC group) regardless of the immunization route (Fig. 15).  
Interestingly, animals receiving encapsulated RB51 with VpB orally, exhibited greater  
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FIG. 13. Light microscopy image of alginate-VpB microspheres loaded with the 
vaccine strain RB51. Brucella abortus RB51 strain was encapsulated into alginate 
microspheres at a concentration of 1.5 x1010 CFU/ml of capsules. Uniform size and 
shape was observed. Microsphere size was measured indicating an average mean size 
of 310µm. 
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FIG. 14. IgG anti-Brucella antibodies in serum from deer vaccinated with RB51. 
Red Deer (n=9) were inoculated SC with 1.5x1010  CFU  of either non encapsulated B. 
abortus RB51, encapsulated B. abortus RB51, encapsulated B. abortus with VpB. 
Control group received empty capsules. Two groups received encapsulated oral 
vaccine (RB51 with alginate) or (RB51 with VpB) at the same dose. 0,6,12,17 and 28 
weeks post- vaccination, serum samples were collected and analyzed for IgG 
determination by ELISA. Results are shown as the means ± standard deviations of 
absorbance at 450. Significant differences were determined by ANOVA **(P<0.005) 
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FIG 15. Lymphocyte proliferative responses of peripheral blood mononuclear 
cells from deer immunized with RB51. Red Deer (n=9) were  vaccinated SC with 
1.5x1010  CFU  of either nonencapsulated B. abortus RB51, encapsulated B. abortus 
RB51 (RB51 with alginate) , encapsulated B. abortus with VpB. Two groups received 
encapsulated oral vaccine (RB51 with alginate) or (RB51 with VpB) at the same dose. 
Control group received empty capsules. Twelve weeks post-vaccination, peripheral 
blood mononuclear cells were isolated, cultured at 37°C for 6 days and pulsed for 18h 
with 1µCi of methyl-[3 H] thymine. Results are expressed as mean CPM± SD. *P<0.05 
are statistically different from the control by ANOVA analysis. 
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proliferation than Red Deer receiving the same formulation via SC inoculation (p <0.3).  
Animals receiving nonencapsulated vaccine failed to mount significant cellular 
responses. 
 Encapsulated RB51 provides enhanced protection against S19 challenge. 
To determine the level of immune protection to infection against B. abortus, deer that 
had been vaccinated with RB51 using either oral or SC routes were challenged 
conjunctivally with a dose of 1x109 CFU of B. abortus S19.  Although not fully virulent in 
the bovine, S19 is virulent in humans and virulence in deer is suggested. In 10 studies 
utilizing over 150 elk, S19 caused abortions in up to 27% of the animals. Furthermore, 
the fact that this strain is not a select agent, permitted field testing.  The protective 
immune response was determined by subtracting the mean number of CFU of S19 
recovered per gram of spleen from deer vaccinated with the nonencapsulated or 
encapsulated vaccine from the mean CFU recovered per gram of spleen from naïve 
non-vaccinated deer.  Seven months post-vaccination (two weeks post-challenge), only 
animals that received encapsulated RB51 with VpB had a significant decrease in 
bacterial load in the spleen (Fig. 16).  Red Deer that received the vaccine orally were 
the only group that was statistically significant compared to the nonencapsulated 
injected RB51 (p <0.04). Animals that were immunized with the VpB capsules given 
orally had a 1.27 log reduction in spleen counts compared to animals vaccinated with 
nonencapsulated RB51 and 1.68 log reduction compared to naïve non-vaccinated 
animals. S19 spleen counts in deer that received the VpB capsules via SC was also 
diminished by 1.21 log compared to the nonencapsulated RB51 and 1.62 logs reduction 
compared to non-RB51 vaccinated controls (p <0.2). 
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FIG. 16 Host response against infection by intraocular S19 exposure. Red Deer  
were vaccinated SC with 1.5x1010  CFU  of either nonencapsulated B. abortus RB51, 
encapsulated B. abortus RB51 (RB51 with alginate), encapsulated B. abortus with VpB. 
Two groups received encapsulated oral vaccine (RB51 with alginate) or (RB51 with 
VpB) at the same dose. Control group received empty capsules. Seven months post- 
vaccination animals were intraocullary infected with 1x109 CFU of S19. Two weeks post- 
infection, animals were euthanized, spleens harvested and the bacterial count per gram 
of spleen was determined. Values are reported as the mean log10 recovery of S19 from 
spleens. Difference in colonization between the vaccinated and control was determined 
by ANOVA *P<0.05. 
59 
 
DISCUSSION 
The ultimate goal of vaccination is to control disease prevalence within and 
originating from reservoirs. To accomplish this goal in the elk population with current 
Brucella vaccines, development of new delivery mechanisms are needed to enhance 
vaccine efficacy. 
Recent data suggests that the manner in which antigen reaches the lymphoid 
organs and how it is delivered to antigen presenting cells is fundamental to induction of 
a good immune response (69).  There is experimental evidence to support the 
observation that microencapsulation serves to modify antigen uptake and processing 
(25, 69).  It has also been suggested that prolonged persistence of the vaccine strain in 
the host is necessary for development of suitable anti-Brucella immunity (37). In an 
effort to develop a more efficient way to present live attenuated vaccines to the 
lymphoid tissue and to increase exposure time of the organism to the host cells, a 
controlled release strategy was developed in which RB51 was encapsulated into 
alginate-VpB microspheres. RB51 was successfully entrapped developing uniform 
spherical batches of capsules with or without VpB.  The addition of this supplement to 
the capsules effectively modified vaccine efficacy as demonstrated by differences in 
cellular and humoral responses.  
Live vaccines are more efficacious than vaccination with heat-killed Brucella or 
cellular extracts in providing a significant level of immunity for protection (64, 82). During 
microsphere formulation, RB51 was exposed to relatively mild conditions that did not 
cause a significant bacterial death (95% viability).  This approach permitted the 
development of  a live, encapsulated  vaccine in contrast to other encapsulation 
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procedures in which the viability of the bacteria is seriously compromised mainly 
resulting from extreme encapsulation conditions needed during the polymerization 
steps.  Harsh conditions include, direct exposure of the bacteria to organic solvents, 
shear stress and ultrasound homogenization have been avoided here (45).  
Oral bait administration of vaccines to wildlife is the most practical and cost 
effective approach.  Since many pathogens access the body via the mucosal surfaces, 
neutralization of the microorganism at the mucosal site would be an ideal method to 
prevent Brucella  from infecting the host.  Successful oral immunization of foxes against 
rabies has been extensively demonstrated using similar techniques and strategies (57, 
62).  Increased efficacy of current Brucella  vaccine strains is also expected if the 
antigen is presented orally, generating an enhanced host response.  By using alginate-
VpB microspheres, capsules are expected to serve as a shield to protect the vaccine 
from degradation in the stomach resulting from exposure to the harsh conditions 
encountered here.  The capsule might also provide a “vaccine package” that could be 
combined with baits for easy delivery. 
Correlates of humoral immunity were assessed with all RB51 vaccine 
formulations and routes of vaccination.  Immunization with RB51 induced remarkable  
IgG levels (total IgG), and these levels were enhanced by microencapsulation 
techniques reported here. For example, oral vaccinates exhibited increasing levels of 
IgG between 17 to 28 weeks, which may reflect the protective benefits of the capsule 
during exposure to the digestive tract.  
Induction of specific cellular mediated immunity (CMI) responses following 
immunization is a hallmark for the establishment of a protective immune response. 
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Published results suggest that in elk a cellular and a humoral response might be 
needed in order to generate a good immunity towards Brucella infections (39, 53). 
Studies performed with the encapsulated RB51, indicated that by 12 weeks 
alginate/VpB capsules administered subcutaneously or orally, were able to stimulate a 
significantly elevated cellular response compared to nonencapsulated RB51.  This data 
suggests that by incorporating the RB51 vaccine into a delivery vehicle, conditions 
necessary to trigger a cellular response confer enhanced protection. Moreover, the 
reduced cellular response elicited by nonencapsulated RB51, corroborated previous 
reports by other researchers (12, 39). 
Following assessment of the initial cellular and humoral responses, three to four 
animals from each group were used to determine the degree of protection against 
challenge  exposure to S19. This strain was utilized mainly because it has been 
previously shown to cause prolonged infection in deer (Thorne, 1980). Among animals 
exposed to an intraocular dose of 1x109 CFU, those immunized with the capsules 
especially those containing VpB exhibited a significant (p <0.04) level of protection. The 
results corroborate the observed cellular and humoral responses, and support the idea 
that capsules serve as a vehicle for enhanced immunogenicity indicating that oral 
delivery is promising and relevant to the current needs of a practical vaccination 
strategy.  Future experiments will utilize greater number of animals and challenge with 
fully virulent organisms. 
 The results observed using nonencapsulated RB51 were similar to those 
obtained in previous studies (54) where RB51 by itself is not sufficient to induce a good 
cellular response or reduce infection (39) in significant levels in  elk.  In contrast, our 
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findings indicate that alginate-VpB encapsulation of live Brucella may be used to 
enhance vaccine efficacy in elk. Furthermore, the observation that oral vaccination 
invoked  humoral and cell mediated responsiveness and a reduction in S19 burden via 
supports the hypothesis of enhanced and prolonged immunity due to a mucosal 
immune stimulation.
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EVALUATION OF ORAL VACCINATION WITH MICROENCAPSULATED S19 
VACCINE STRAIN AGAINST B. abortus WILD-TYPE CHALLENGE IN RED DEER 
 
INTRODUCTION 
 The prevalence of brucellosis within Red Deer populations in the Greater 
Yellowstone area constitutes a serious public health problem mainly because of the 
threat of free-ranging animals transmitting the infection to cattle. Within the last years, a 
number of Brucella-infected cattle herds have been identified in Wyoming and Idaho, in 
which the source of infection was presumed to be Bison and Elk (33). The 
seroprevalence of the disease can be attributed to the management practices 
implemented during winter feeding. Artificial winter feeding in the Greater Yellowstone 
area has resulted in significant congregations of elk in feeding grounds increasing the 
risk of exposure to the bacterium (30).  
 Current vaccine strains used to control the disease in cattle have proven to be 
less effective in wildlife populations. Experimental data suggest that S19 prevents 
abortion in only 30% of the population, while RB51 when given in a conventional  format 
is ineffective against the disease (12, 39, 41, 71). Difficulties with vaccination arise not 
only because of the reduced efficacy of vaccine strains, but also resulting from the 
delivery method used to immunize the animals. Although its efficacy in elk is not 
comparable to its performance in cattle,  vaccination with  Brucella abortus S19 it is the 
best alternative and has been used since 1985 for elk vaccination. The methodology 
implemented to immunize these animals includes the use of biobullets containing live 
S19 to ballistically vaccinate Red Deer from distances of 30 meters (53). 
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Inconveniencies associated with this methodology include excessive time, labor, 
logistics and elevated cost.  
 It is acknowledged that the removal of winter feeding grounds is not a viable 
strategy for the short-term control  of brucellosis in the Yellowstone area wildlife 
population. Alternative control measures such as improvement of vaccine efficacy and a 
more feasible methodology to immunize animals needs further investigation, not only to 
reduce the prevalence of the disease, but also to prevent the transmission of infected 
elk herds to bison and cattle, and more importantly to humans.  
 We have investigated the possibility of delivering the current licensed vaccine 
strain S19 in a controlled microencapsulated format. We have previously demonstrated 
an increased efficacy when live Brucella vaccines candidates are delivered in 
microspheres containing alginate, a naturally occurring biopolymer combined with a 
novel protein of the parasite Fasciola hepatica, Vitelline protein B (VpB) which possess 
an unusual enzymatic resistance to protein breakdown, modifying  the erosion time of 
the capsule content (61).  In the present study, we evaluated the vaccine efficacy when 
delivered by either oral or subcutaneous route, since the former represents the most 
feasible way to deliver vaccines in wildlife populations. 
 
MATERIALS AND METHODS 
 Animals. Fifty- four, 1- to 2- year- old Red Deer (Cervus elaphus elaphus) 
females were bought from a privately owned tuberculosis and brucellosis commercial 
free herd as an animal model for Rocky Mountain elk (Cervus elaphus nelsoni) due to 
their close genetic relationship ease of handling and animal husbandry.  Upon arrival, 
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animals were re-tested for anti Brucella IgG levels (total IgG) by ELISA, dewormed  
using Moxidectin and Cydectin and allowed to acclimate for 3 months.  For experimental 
purposes Red Deer were randomly assigned into 6 different treatment groups (n=9).  All 
animal care and experimental procedures were performed in compliance with 
institutional animal care and guidelines. 
 B. abortus S19 and wild-type 2308 cultures. Bacteria used in these 
experiments include B. abortus S19 used as the vaccine candidate and B. abortus 
virulent strain 2308. Brucella was grown on tryptic soy agar (TSA) plates incubated at 
37°C in atmosphere containing 5% (w/v) CO2 for 72 hours.  Bacteria were harvested 
from the plates by scraping them off the plate surface into phosphate buffered saline 
(PBS). The harvested bacteria were pelleted by centrifugation at 3000 x g and the pellet 
resuspended in fresh PBS.  This step was repeated two more times and the 
concentration of bacteria determined by optical density using a standardized curve of 
optical density (Klett units) vs. colony forming units (CFU).  The concentration of viable 
organisms was verified retrospectively by plating serial dilutions of cell suspensions.  
 Preparation of B. abortus S19-loaded microspheres. Alginate beads loaded 
with 1.5x1010 CFU/ml of the vaccine strain S19 were prepared as previously described 
for live bacteria (1) with several modifications.  Briefly, enumerated live S19 vaccine 
strain (total 1.5x1011 for 10 doses) was re-suspended in a total of 100µl of MOPS (3-[N-
Morpholino] propanesulfonic acid) buffer (10mM MOPS, 0.85% NaCl, pH 7.4) and 
mixed with 10 mls of alginate solution (1.5% sodium alginate, 10mM MOPS, 0.85% 
NaCl, pH 7.3).  Three hundred µm spheres were obtained by extruding the suspension 
through a 200 micron nozzle into a 100mM calcium chloride solution and stirred for 15 
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minutes using the Inotech encapsulator I-50 (Inotech Biosystems International, 
Rockville USA).  In order to permanently crosslink the capsule, microspheres were 
resuspended in MOPS buffer supplemented with 0.05% (w/v) poly-L-lysine (PLL, MW 
22,000) for 15 minutes.  Following two successive washes, the beads were washed with 
stirring to a MOPS buffer supplemented with 0.03% (w/v) alginate for 5 min to apply a 
final outer coating.  The addition of VpB as a component of the alginate core was 
achieved by the supplementing the mixtures described above with 1 mg of VpB to the 
bacteria-alginate suspension. Extrusion and capsule formation was performed exactly 
as described above. All capsules were stored at 4°C in MOPS buffer until use.   
 Bacterial enumeration and viability.  To determine the bacterial content per ml 
of alginate particles,  1 ml  of capsules was removed from the encapsulator prior to 
permanent crosslinking with poly-L-lysine or VpB with poly-L-lysine.  The capsules were 
allowed to settle and washed twice with MOPS buffer and particles were dissolved 
using 1 ml of depolymerization solution (50 mM Na3-Citrate, 0.45% NaCl 10mM MOPS, 
pH 7.2) with stirring for 10 min.  Bacterial number (CFU/ml) per ml of capsules was 
determined by plating onto TSA plates. 
 Immunization of Red Deer. Red Deer were randomly distributed into 6 different 
treatment groups (n=9). Animals were given a single dose of vaccine containing either 
(a) encapsulated S19 (SC), (b) encapsulated S19 with alginate and VpB (SC), (c) 
encapsulated S19 (oral), (d) encapsulated S19 with alginate and VpB (oral). Control 
groups received  1.5x1010 CFU of either  (a) Nonencapsulated S19 (SC)  or (b)  Empty 
capsules (no bacteria entrapped) (SC).  
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 Detection of Brucella -specific antibody levels. To determine the level of 
anti-Brucella-specific antibody in serum, blood samples were collected by jugular 
venipuncture immediately prior to vaccination, and at 6, 12, and 17 post-vaccination. 
Serum samples were evaluated for total IgG determination by ELISA.  Heat killed and 
sonicated  B. abortus 2308 lysate was used as antigen to coat 96 well plates (Nunc-
Immuno plates, high binding protein) at a protein concentration of 25µg/well.  After 
overnight incubation at 4°C, plates were washed with PBS containing 0.05% (w/v) 
Tween-20, and blocked in the same solution supplemented with 0.25% (w/v) BSA to 
prevent non-specific binding.  The blocking buffer was removed and deer serum 
samples diluted 1:100 in blocking buffer were incubated for 2 hrs at room temperature 
with rocking.  Following three more washes, horseradish peroxidase conjugated goat 
anti-deer IgG (KPL, USA) was added to the wells at a dilution 1:1000 and incubated at 
room temperature for 1 hr.  After incubation, plates were washed as describe above and 
the peroxidase substrate o-phenylenediamine dihydrochloride (OPD) (Sigma-Aldrich, 
USA) was added following manufacturer’s instructions and incubated for no more than 
20 min.  The reaction was stopped by the addition of 50µl of 0.5M NaOH and the 
absorbance measured at 450nm (A450).  All assays were performed in triplicate and 
repeated at least two times.  
 Lymphocyte proliferation assay from peripheral blood mononuclear cells. 
At 17 weeks post-vaccination, mononuclear cells were isolated from the buffy coats of 
peripheral blood as previously described with some modifications(74).  Briefly, 2 x 105 
cells/well were seeded in 96 well plates (Falcon, Becton Dickinson, USA) in RPMI 
medium containing 10% (v/v) fetal bovine serum, 1mM L-glutamine, and 1mM non-
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essential amino acids.  Cells were stimulated with either (a) B. abortus S2308 (wild-
type) lysate at a concentration of 12.5µg/ml, (b) Concanavalin A (5µg/ml) or  (c) medium 
alone during incubation for 6 days at 37°C in atmosphere containing 5% (v/v) CO2 . 
Following incubation, 1µCi of methyl-[3H] thymine was added to each well and 
incubation was continued for an additional 18 hours.  The cells were harvested onto 
glass fiber filters using a 96 well plate cell harvester and the incorporated [3H]thymidine 
was determined using a Beckman liquid Scintillation counter.  Data is represented as 
mean counts per minute (CPM) ± standard deviation. 
Efficacy of vaccination.  One year post-vaccination, two to three animals from 
each group were housed into BL3- facility buildings (5 to 6 animals per building) and 
acclimated for two weeks prior to challenge. Animals were exposed intraocullary using a 
challenge dose of 1x 109 / deer of B. abortus wild-type 2308 as confirmed by plating 
serial dilutions onto TSA plates. Two weeks post-challenge, animals were euthanized 
and spleens, lungs and liver were harvested, weighed and homogenized in 1 ml of 
peptone saline per gram of tissue for 5-10 minutes using a stomacher. Additionally 
parotid, mesenteric and mammary lymph nodes were extracted and each lymph node 
was homogenized in 1ml of peptone saline.  One hundred microliter portions of each 
sample were serially diluted and plated in duplicate onto Farrell’s media (TSA 
supplemented with 10% (v/v) horse serum, 2% (w/v) dextrose and Oxoid Brucella 
supplement).  Three to five days post-inoculation bacterial counts were enumerated.  
Results are represented as the mean CFU per gram of tissue ± SEM. For lymph nodes 
results are represented as the mean CFU per lymph node ± SEM. 
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 Statistical procedures. IgG levels elicited by vaccination are expressed as the 
mean A450±SD for each group.  For determination of cellular responses, counts per 
minute (CPM) from each group are expressed as the mean CPM±SD.  Efficacy of 
vaccination was expressed as mean log CFU±SEM for each group.  The significance of 
differences between groups was determined by analysis of variance (ANOVA) using 
Prism software (GraphPad).  A P value <0.05 is considered statistically significant. 
 
RESULTS 
 Encapsulated S19 elicited Brucella-specific IgG responses. Serum collected 
at different times post-vaccination was assayed for the presence of Brucella-specific 
antibodies by ELISA.  Immunization with S19 elicited an IgG response in SC-vaccinates 
that was significantly different from naïve animals by 6 weeks post-vaccination 
(p<0.005). Animals that received the oral vaccine elicited lower detectable IgG levels at 
all time points, but interestingly, only animals that received the oral vaccine with VpB in 
the formulation had increasing levels of IgG. The IgG peak  in Red Deer that received 
this formulation was delayed up to 17 weeks post-vaccination compared to all of the 
other groups were IgG peaked at  6 weeks post-vaccination (Fig 17).
 Encapsulated S19 enhances cellular immune responses. To determine the 
possible effect of encapsulation in the cellular response elicited in Red Deer vaccinated 
with S19, a cellular proliferation assay was performed.  Animals were bled 17 weeks 
post-vaccination, and blastogenesis was performed using cells isolated from the buffy 
coat.  
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FIG 17. IgG anti-Brucella antibodies in serum from deer vaccinated with S19. Red Deer 
(n=9) were inoculated SC with 1.5x1010  CFU  of either non encapsulated B. abortus S19, 
encapsulated B. abortus S19, encapsulated B. abortus with VpB. Control group received empty 
capsules. Two groups received encapsulated oral vaccine (S19 with alginate) or (S19 with VpB) 
at the same dose. 0,6,12 and 17 weeks post- vaccination, serum samples were collected and 
analyzed for IgG determination by ELISA. Results are shown as the means ± standard 
deviations of absorbance at 450. Significant differences were determined by ANOVA **(P<0.005) 
d Encapsulated B. abortus S19 SC, e Encapsulated B. abortus with VpB SC, f Non encapsulated 
B. abortus Stimulation was performed in vitro as described in the Materials and Methods section. 
Only animals receiving the encapsulated vaccine in which VpB was added to S19 SC 
(Differences were significant at all timepoints). 
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 The core formulation via a subcutaneous route exhibited statistically significant 
proliferative responses compared to naïve animals. (p <0.05). Animals receiving 
nonencapsulated vaccine failed to mount significant cellular responses (Fig 18). 
 Evaluation of immune protection provided by encapsulated B. abortus 
S19.  In order to determine the effect of encapsulation on immunization, the level of 
protection provided by vaccination with either encapsulated and nonencapsulated S19 
was evaluated against wild-type challenge at 1 year post vaccination. Recovery of 
challenge organism in spleen, lung, liver and parotid, mesenteric and mammary lymph 
nodes was evaluated.  Two weeks post-challenge, only Red Deer vaccinated orally with 
the encapsulated vaccine containing VpB in the formulation had a statistically significant 
decrease in bacterial load in the spleen relative to naïve deer. Animals vaccinated using 
this formulation had a 1.85 logs reduction (p <0.0005) in bacterial burden (Fig 19) 
compared to naïve animals. Colonization of wild-type 2308 in lung and livers was not 
significant different between the controls and the immunized groups but animals that 
received the encapsulated oral vaccine with VpB had a reduced bacterial burden 
(p>0.05)  (Fig 20, 21).  Parotid lymph nodes that were closer to the site of inoculation 
exhibited the highest CFU counts (Fig 22, 23, 24). In accordance to the reduced 
recovery of wild-type organism in the spleen, only the oral vaccinees that received the 
encapsulated vaccine with VpB, had a significant reduction in bacterial burden in the 
parotid lymph nodes (p<0.005) (Fig 24).  
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FIG 18. Lymphocyte proliferative responses of peripheral blood mononuclear 
cells from deer immunized with S19. Red Deer (n=9) were  vaccinated SC with 
1.5x1010  CFU  of either nonencapsulated B. abortus S19, encapsulated B. abortus S19 
(S19 with alginate), encapsulated B. abortus with VpB. Two groups received 
encapsulated oral vaccine (S19 with alginate) or (S19 with VpB) at the same dose. 
Control group received empty capsules. Twelve weeks post-vaccination, peripheral 
blood mononuclear cells were isolated, cultured at 37°C for 6 days and pulsed for 18h 
with 1µCi of methyl-[3 H] thymine. Results are expressed as mean CPM± SD. *P<0.05 
are statistically different from the control by ANOVA analysis. 
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 FIG 19. Vaccination efficacy against 2308 wild-type challenge. Red Deer  
were vaccinated SC with 1.5x1010  CFU  of either nonencapsulated B. abortus 
S19, encapsulated B. abortus S19 (S19 with alginate), encapsulated B. abortus 
with VpB. Two groups received encapsulated oral vaccine (S19 with alginate) or 
(S19 with VpB) at the same dose. Control group received empty capsules. One 
year post- vaccination animals were intraocullary infected with 1x109 CFU of wild-
type 2308. Two weeks post- infection, animals were euthanized, spleens 
harvested and the bacterial count per gram of spleen was determined. Values 
are reported as the mean log10 recovery of 2308 from spleens. Difference in 
colonization between the vaccinated and control was determined by ANOVA 
*P<0.05.
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FIG 20. Bacterial recovery from lung tissue in Red Deer challenged with B. 
abortus 2308. Red Deer  were vaccinated SC with 1.5x1010  CFU  of either 
nonencapsulated B. abortus S19, encapsulated B. abortus S19 (S19 with alginate), 
encapsulated B. abortus with VpB. Two groups received encapsulated oral vaccine (S19 
with alginate) or (S19 with VpB) at the same dose. Control group received empty 
capsules. One year post- vaccination animals were intraocullary infected with 1x109 CFU 
of wild-type 2308. Two weeks post- infection, animals were euthanized, lungs harvested 
and the bacterial count per gram of lung was determined. Values are reported as the 
mean log10 recovery of 2308 from spleens. Difference in colonization between the 
vaccinated and control was determined by ANOVA *P<0.05. 
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FIG 21. Bacterial recovery from liver tissue in Red Deer challenged with B. 
abortus 2308. Red Deer  were vaccinated SC with 1.5x1010  CFU  of either 
nonencapsulated B. abortus S19, encapsulated B. abortus S19 (S19 with alginate), 
encapsulated B. abortus with VpB. Two groups received encapsulated oral vaccine (S19 
with alginate) or (S19 with VpB) at the same dose. Control group received empty 
capsules. One year post- vaccination animals were intraocullary infected with 1x109 CFU 
of wild-type 2308. Two weeks post- infection, animals were euthanized, livers harvested 
and the bacterial count per gram of livers was determined. Values are reported as the 
mean log10 recovery of 2308 from spleens. Difference in colonization between the 
vaccinated and control was determined by ANOVA *P<0.05. 
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FIG 22. Bacterial recovery from parotid lymph nodes post-challenge with B. 
abortus 2308. Red Deer  were vaccinated SC with 1.5x1010  CFU  of either 
nonencapsulated B. abortus S19, encapsulated B. abortus S19 (S19 with alginate), 
encapsulated B. abortus with VpB. Two groups received encapsulated oral vaccine (S19 
with alginate) or (S19 with VpB) at the same dose. Control group received empty 
capsules.Two weeks post-challenge, animals were euthanized, parotid lymph nodes 
were harvested, resuspended in 1ml of peptone saline, homogenized and plated for 
bacterial enumeration. Results are represented as the mean CFU recovered per lymph 
node. Difference in colonization between the vaccinated and control was determined by 
ANOVA *P<0.05. 
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FIG 23. Bacterial recovery from mesenteric lymph nodes post-challenge with B. 
abortus 2308. Red Deer  were vaccinated SC with 1.5x1010  CFU  of either 
nonencapsulated B. abortus S19, encapsulated B. abortus S19 (S19 with alginate), 
encapsulated B. abortus with VpB. Two groups received encapsulated oral vaccine (S19 
with alginate) or (S19 with VpB) at the same dose. Control group received empty 
capsules.Two weeks post-challenge, animals were euthanized, parotid lymph nodes 
were harvested, resuspended in 1ml of peptone saline, homogenized and plated for 
bacterial enumeration. Results are represented as the mean CFU recovered per lymph 
node. Difference in colonization between the vaccinated and control was determined by 
ANOVA *P<0.05. 
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FIG 24. Bacterial recovery from mammary lymph nodes post-challenge with B. 
abortus 2308. Red Deer  were vaccinated SC with 1.5x1010  CFU  of either 
nonencapsulated B. abortus S19, encapsulated B. abortus S19 (S19 with alginate), 
encapsulated B. abortus with VpB. Two groups received encapsulated oral vaccine (S19 
with alginate) or (S19 with VpB) at the same dose. Control group received empty 
capsules.Two weeks post-challenge, animals were euthanized, parotid lymph nodes 
were harvested, resuspended in 1ml of peptone saline, homogenized and plated for 
bacterial enumeration. Results are represented as the mean CFU recovered per lymph 
node. Difference in colonization between the vaccinated and control was determined by 
ANOVA *P<0.05.
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DISCUSSION 
       Wildlife vaccination represents a practical tool for the control of transmissible 
diseases that represent a risk to public health. Common issues with vaccines for this 
population includes: the need of a good protective immunity, minimization of side 
effects, ease of handling and administration, and a reduced cost of production and 
delivery. Current vaccination strategies used to control brucellosis in the Greater 
Yellowstone area do not fulfill these requirements: B. abortus S19 vaccine only confers 
protection in 30% of the population, can produce abortion in a low percentage of the 
vaccinates and it is ballistically delivered, increasing the cost and risk of administration. 
By using microencapsulation techniques we studied the ability to enhance S19 efficacy 
and provide an easier delivery method to administer the vaccine in Red Deer.  
Experimental evidence suggests that live vaccines are more efficacious against 
brucellosis than killed vaccines (11, 38). Vaccination results using B. abortus S2308, 
S19 and RB51 suggests that the persistence of the Brucella vaccine strain is also 
critical to confer protection (37, 38). These two observations have to be taken into 
consideration when designing new vaccines or vaccination strategies. In this study, we 
were able to develop a method of vaccine delivery in which the viability of the bacteria is 
not compromised due to the mild procedure used to encapsulate the vaccine. Also, we 
tested the ability of the vaccine to protect against wild-type challenge when the 
immunogen is given by an oral route. Oral administration was analyzed because the 
most cost-effective method of vaccinating wildlife animals would be to incorporate the 
vaccine in bait. 
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Correlates of humoral immunity were monitored in all S19 vaccine formulations 
and routes of vaccination. Immunization with S19 induced remarkable IgG levels even 
when the vaccine was given in a microencapsulated format (Fig. 12). Animals that 
received VpB in the formulation orally, were able to mount increasing IgG levels that 
animals that did not receive VpB in the formulation fail to induce, which may reflect the 
increased resistance of the capsule to the stomach conditions due to the highly 
proteolitic resistance to breakdown of VpB.  
Previous investigations suggests that induction of specific cell mediated immune 
responses following immunization is important for the establishment of a protective 
immune response in Red Deer (12, 53). Studies performed with the encapsulated S19, 
indicated that by 17 weeks only alginate/vpB capsules administered subcutaneously 
were able to stimulate a significant elevated cellular response compared to naïve 
animals. Red Deer that received the same formulation orally did show enhanced cellular 
responses but was not statistically significant (P<0.1). This data suggests that by 
incorporating the S19 vaccine into microcapsules, conditions necessary to trigger a 
cellular response are provided. Further studies adjusting the VpB concentration for the 
oral formulation are still needed to obtain the response observed with the subcutaneous 
vaccination.  
To determine the degree of protection against wild-type challenge, two to three 
animals from each group were housed in large animal BL3 facility buildings.  Because of 
federal regulations and difficulty in housing these animals, group sizes were very 
limited.  Among animals exposed to an intraocular dose of 1x109  CFU of wild-type 2308, 
the highest bacterial burden was observed from spleens and parotid lymph nodes. This 
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finding was expected due to the proximity of these lymph nodes to the site of 
inoculation. When vaccination efficacy was analyzed based on CFU reduction in spleen 
of immunized vs. naïve but challenged deer, only animals that received the vaccine 
orally within capsules containing VpB in the formulation  exhibited a significant 
(p<0.005) degree of protection compared to the control. In accordance with this 
observation, this group also exhibited the lowest numbers of recoverable bacteria in 
lungs and livers. Interestingly, bacterial counts in the parotid lymph nodes was also 
diminished (p<0.005). These results support the idea of induction of mucosal immunity 
by the oral vaccine.  
Prevention of loss of S19 viability inside the stomach, is one of the most critical 
steps toward the development of good mucosal immunity by oral vaccination.  Since the 
microencapsulated oral vaccine elicited stronger immune responses than 
nonencapsulated vaccine, we suggest that the alginate-VpB formulation protected the 
vaccine from the harsh enzymatic environment encountered in the stomach. This 
correlates with the observations made by other groups, in which alginate has be proven 
to resist low pH degradation (75). The exact mechanism of protection and delivery 
remains to be determined. These results are promising to the current needs for an oral 
bait vaccine. 
It is also important to mention that this study was conducted over a year, in 
which animals were vaccinated only once. If the vaccine is given as an oral bait, 
probably animals will be naturally boosted and this might enhance even more the 
vaccine efficacy or create tolerance that would be detrimental to protection. Also, the 
intraocular dose used for challenge is probably more severe than natural exposure of 
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elk to B. abortus in the field, if indeed the challenge in the field is less severe, protection 
against field challenge could be even higher that observed in this experimental 
challenge study. Further studies to address the effect of multiple doses of vaccine and 
different challenge doses with higher animal  numbers are currently under investigation. 
In conclusion, a novel method of vaccination was examined using a controlled 
release mechanism. Collectively, our preliminary data demonstrate that oral vaccination 
of Red Deer via alginate-vpB encapsulation of S19 is a robust and efficient way to 
induce protective immune responses in Red Deer. We were able to observe that 
protection against 2308 wild-type challenge was sustained for a period of at least 1 year 
post-vaccination. This methodology of vaccination might be an alternative to enhance 
vaccines that are currently used for vaccination. This might be a safe and effective 
means of controlling brucellosis in the Greater Yellowstone area. 
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EVALUATION OF luxR DELETION IN S19 VACCINE AND DETERMINATION OF ITS 
POTENTIAL AS A VACCINE WHEN DELIVERED IN A MICROENCAPSULATED 
DELIVERY VEHICLE 
 
INTRODUCTION 
 Brucella abortus S19 live vaccine has been extensively used to prevent the 
disease in cattle (50). This strain was first isolated from the milk of a Jersey cow in 1923, 
and after being kept in the laboratory at room temperature it became attenuated (50). 
Extensive efficacy studies conducted in cattle with this vaccine, have demonstrated that 
70% of the vaccinates are protected from a wild-type exposure (50). Effectiveness 
depended on a series of variables including age of vaccination, prevalence of the 
disease in vaccinated herds, dose and route of vaccination (50, 64). Although S19 is of 
low virulence for cattle, there is an incidence between 1% up to 2.5% of abortion rates, 
when the vaccine is given to pregnant animals (64). A less frequent adverse effect of 
strain 19 vaccination is the development of an arthropathy associated with Brucella 
antigen-containing immune complexes (50, 64). In many developing nations 
immunizations derived from S19 vaccine have been evaluated in humans. In the former 
Soviet Union, administration of live S19 preparations were immunogenic and protection 
was achieved and considered to last 1 year but, caused a modest but notable incidence 
of clinical cases, as well as a hypersensitivity reaction (10, 50).  
 Previous research in our lab, has identified Brucella melitensis genes required for 
virulence and survival via transposon mutagenesis (3, 34). Among these, vjbR 
(BMEI1116), encoding the luxR-like quorum sensing-related transcriptional regulator is 
required for virB expression (17). luxR mutants of B. melitensis were highly attenuated 
for virulence in mice and macrophages. BALB/c mice immunized with the luxR mutant 
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were protected against wild-type challenge, did not provoke any local or adverse 
reactions in mice, making such mutants ideal vaccine candidates.  In the present study,  
the effects of eliminating the luxR gene from B. abortus S19 were evaluated in vitro and 
in BALB/c mice. The capacity of B. abortus S19ΔluxR::kan mutant to elicit Brucella 
specific immune responses was also evaluated. Furthermore, to try to enhance 
vaccination efficacy, the knockout was encapsulated into microspheres with the aim of 
producing vaccines that are safer and still very effective. 
MATERIALS AND METHODS 
 Mice.  One hundred and fifty 4 to 6-week old female BALB/c mice were obtained 
from the Jackson Laboratory (Bar Harbor, ME).  All experimental procedures and animal 
care were performed in compliance with institutional animal care regulations. 
 Bacterial strains.  Bacteria used in these experiments include B. abortus S19, 
B. abortusΔluxR::Kan and B. abortus virulent strain 2308. Bacteria were grown on tryptic 
soy agar (TSA) at 37°C with 5% (v/v) CO2. For B. abortusΔluxR::Km, the medium was 
supplemented with kanamycin (100µg/ml).  Following 3 days of incubation, bacteria were 
harvested from the surface of plates into phosphate buffered saline (PBS). The bacteria 
were pelleted, and washed twice by resuspension in buffer containing MOPS (10mM 
MOPS, 0.85% NaCl, pH 7.4), and resuspended to a final concentration of 1x106 CFU /ml 
for encapsulation, or 1x105 CFU in 100µl of PBS of  nonencapsulated based upon optical 
density (OD) readings using a Klett meter and a standardized curve.  The actual viable 
counts were confirmed by serial dilution and plating of portions onto TSA plates with or 
without antibiotic. To inoculate mice, bacteria was harvested the same day of challenge, 
and the density was determined using a Klett meter. Inoculum doses were plated 
retrospectively to determine the number of organisms inoculated. 
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 Transfection of Brucella was performed via electroporation, using cultures 
prepared from a frozen stock and grown to confluence on TSA at 37°C for 3 days. 
Bacteria were harvested into PBS to yield a final suspension containing approximately 4 
x 1011 CFU/ml, estimated using a Klett Meter. Escherichia Coli cultures were grown on 
Luria-Bertani (Difco, Laboratories) plates overnight at 37°C with or without kanamycin 
(100mg/liter), carbenicillin (100mg/liter), or chloramphenicol (50mg/liter).  
 Plasmid construction.  Primers were designed to amplify sequences flanking 
the genes following a methodology previously described (37). 
 Construction of S19Δ luxR::kan deletion mutant. The marked deletion mutant 
S19ΔluxR::kan was constructed in S19 as previously described with some modifications 
(37). Briefly, the mutant was created in B. abortus S19  via allelic exchange following 
electroporation of the marked plasmid into S19. Bacteria were grown as described above 
and pelleted via centrifugation at 1,700 x g for 15 min at 4°C. The cell pellet was washed 
three times with ice-cold sterile water. After the final wash, the cells were resuspended in 
1 ml sterile water. The bacterial cell suspension was used in each electroporation with 1 
µg DNA in a prechilled 1-mm gap cuvette (Bio-Rad, California) and shocked in a BTX 
electroporation apparatus set at 2.2 to 2.5 kV. SOC-B (6% [wt/vol] tryptic soy broth, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) medium was 
immediately added to the cuvette, transferred to microcentrifuge tubes, and incubated 
overnight at 37°C with agitation. Following incubation, the entire culture was plated onto 
TSA containing kanamycin. Verification of mutant genotypes was obtained via PCR and 
Southern blot analysis (data not shown). 
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 Evaluation of B. abortus S19ΔluxR::kan in J774A.1 macrophages. Murine 
macrophage-like J774.A1 (ATCC TIB-67) were used to assess S19ΔluxR::kan mutant 
survival compared to the parental B. abortus S19.  Macrophage survival assays were 
performed as previously described with some modifications (58). Briefly, macrophages 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% (v/v) fetal 
bovine serum, 1mM L-glutamine, and 1mM nonessential amino acids.  Monolayers of 
macrophages containing 2.5 x105 cells per well were infected at a multiplicity of infection 
of 1:100, at 37°C with either S19ΔluxR::kan, S19  or wild-type 2308.  Thirty minutes post 
infection, cells were washed twice with medium without antibiotics and then incubated 
with 50µg/ml of gentamicin (Invitrogen,USA) for 30 min to kill any extracellular bacteria. 
One and 48 hours post-infection, macrophages were lysed using 0.05% (v/v) Tween-20, 
and bacteria collected.  Brucella entry and survival was determined by performing serial 
dilutions and plating onto TSA plates with or without antibiotic.  All assays were 
performed in triplicate and repeated at least three times.  
 Evaluation of B. abortus S19ΔluxR::kan attenuation in mice. Female BALB/c 
mice were used to evaluate survival of the S19ΔluxR::kan mutant.  Briefly, 4-to 6-week-
old mice were intraperitoneally inoculated with a total of 1x106 CFU of either mutant or 
the parental strain.  Groups of 5 mice were euthanized via carbon dioxide asphyxiation 
at 1,3,5,7 and 9 weeks post inoculation. At each time point, spleens were collected, 
weighed and homogenized in 1ml of peptone saline.  Serial dilutions were prepared, and 
100µl aliquots of the different dilutions were plated in duplicate onto TSA or TSA/kan. 
Levels of infection were expressed as the mean ± standard error of the mean (SEM) of 
individual log CFU/ spleen. 
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 Histopathology. Twelve 4-6 week-old female BALB/c mice were distributed into 
groups of 3 mice and inoculated with 1x105 CFU per mice of either (a) S19, (b) 
S19ΔluxR::kan, (c) B. abortus 2308, (d) PBS. Two weeks post inoculation, which 
corresponded to the peak of splenomegaly, animals were euthanized by CO2 
asphixiation, and spleen, lungs, liver, kidneys and heart were harvested, fixed in 10% 
buffered formalin, paraffin embedded and stained with hematoxylin and eosin following a 
standard procedure. Histological changes were assessed between treatment groups.  
 Preparation of B. abortus -loaded microspheres.  Alginate beads were 
prepared as previously described with some modifications(1). Briefly, 6x106 CFU of the 
live B. abortus S19ΔluxR::kan or B. abortus S19 was re-suspended in 1ml of MOPS 
buffer (10mM MOPS, 0.85% NaCl, pH 7.4) and mixed with 5ml of alginate solution (1.5% 
sodium alginate, 10mM MOPS, 0.85% NaCl, pH 7.3). VpB  was added as a component 
of the alginate core (S19ΔluxR::kan/core) by the addition of 1mg of VpB to the bacteria-
alginate suspension described above. Spheres were obtained by extruding the 
suspension through a 200 micron nozzle into a 100mM calcium chloride solution and 
stirred for 15 minutes using the Inotech encapsulator I-50 (Inotech Biosystems 
International, Rockville USA).  After extrusion of the bacteria-alginate mixture into the 
CaCl2, the capsules were washed twice with MOPS for 5 minutes and further crosslinked 
with 0.05% poly-L-lysine (PLL, MW 22,000 Sigma, USA) for 10 minutes.  Following two 
successive washes, the beads were stirred in a solution of 0.03% (w/v) alginate for 5 min 
to apply a final outer shell and washed twice with MOPS before storage at 4°C. To 
determine the bacterial viability post- encapsulation, 1 ml  of capsules was removed from 
the encapsulator prior to permanent crosslinking with poly-L-lysine.  The capsules were 
allowed to settle and washed twice with MOPS buffer and particles were dissolved using 
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1 ml of depolymerization solution (50 mM Na3-Citrate, 0.45% NaCl 10mM MOPS, pH 
7.2) with stirring for 10 min.  Bacterial number (CFU/ml) per ml of capsules was 
determined by plating onto TSA plates. 
 Immunization of mice.  Twenty 4-6 week-old female BALB/c mice were 
randomly distributed into groups of 5 mice for intraperitoneally (IP) vaccination. Animals 
were given a single dose of vaccine containing 1x105 CFU of  either (a) encapsulated B. 
abortus S19ΔluxR::kan in alginate with VpB inside the capsule (S19ΔluxR::kan /VpB 
core),  (b) Nonecapsulated B. abortus S19ΔluxR::kan, Control groups received 1x105 
CFU of either (a) nonencapsulated S19,  (b) Empty capsules (no bacteria entrapped) 
resuspended in 100µl of MOPS.  
 Evaluation of Brucella specific antibody.  To determine the effect of 
encapsulation in the production of anti-Brucella-specific antibody in sera from inoculated 
mice, 100µl of blood was taken from each mouse after 0, 3, 7 weeks post vaccination 
and 1 week post-challenge. Serum was separated and used for IgG1 and IgG2a 
determination by ELISA.  Heat killed and sonicated B. abortus whole cell antigen was 
used to coat 96 well plates (Nunc-Immuno plates) at a concentration of 25µg total 
protein/well.  Following overnight incubation at 4°C, plates were washed, blocked with 
0.5 ml of blocking buffer [0.25% (w/v) BSA] then  incubated  with mouse sera diluted 
1:100 in the same blocking buffer for 1 hr at room temperature.  Following extensive 
washing to remove unbound antibody, goat anti-mouse IgG1 or IgG2a horseradish 
peroxidase (HRP) conjugate  (Serotec, USA) was added at a concentration of 500ng/ml 
of antibody and incubation continued for an additional hour. Following this incubation, 
the plates were washed again and  HRP substrate was added, and incubated for 18 
minutes.  The reaction was stopped by addition of 50 µl of 0.5M NaOH and the 
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absorbance measured at 450 nm (A450).  All assays were performed in triplicate and 
repeated at least three times. 
 Efficacy of vaccination.  At selected times post vaccination,  mice (n=5 per 
group) were challenged IP using 1x105 CFU/mouse of B. abortus wild-type 2308.  One 
week post challenge, mice were euthanized by CO2 asphyxiation and  spleens were 
removed, weighed and homogenized in 1ml of peptone saline.  Serial dilutions were 
prepared and 100 µl portions were plated onto TSA plates.  In some instances, 200-
1000µl of spleen homogenate was plated to determine organism recovery.  To 
differentiate between vaccine candidate and the challenge strain, each dilution was also 
plated on TSA with kanamycin to identify any residual kanamycin resistant vaccine strain 
present.  Levels of infection were expressed as the mean ± SEM of individual log10 
CFU/spleen. The efficacy of the vaccine compared to naïve animals was determined by 
subtracting the mean CFU/spleen recovered from mice vaccinated with the 
nonencapsulated or encapsulated  vaccine from the mean CFU/spleen  recovered from 
naïve non-vaccinated but challenged mice. The efficacy of the encapsulated vaccine 
compared to the nonencapsulated vaccine was determined by subtracting the mean 
CFU/spleen recovered from mice vaccinated with the capsules from the mean 
CFU/spleen recovered from mice immunized with the nonencapsulated vaccine.   
 Determination of TNFα cytokine production In vivo. At 0, 3, 7 weeks post-
vaccination and 1 week post-challenge, BALB/c mice animals were bleed and serum 
was  obtained from each individual mouse for cytokine determination. Quantification of 
TNFα was determined by ELISA (Ebioscience, USA) following manufacturer’s 
instructions. For each cytokine, standards ranging from 0.2 to 1000 pg/ml were 
performed. Background levels obtained from t=0 were subtracted from the samples and 
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the differences between the encapsulated and nonencapsulated formulations at each 
timepoint were determined by ANOVA. Results are expressed as the mean pg/ml of 
each cytokine. 
 Statistical procedures. Macrophage infection and survival was expressed as 
the mean log CFU ± SD for each group. Intensity of infection (bacterial clearance and 
efficacy of vaccine) at each time point was expressed as mean log CFU±SEM for each 
group. IgG production was expressed as the mean absorbance ± SEM.  Cytokine 
production in vitro was expressed as mean cytokine concentration ± SD for each group 
of five mice.  The significance of differences between groups was determined by 
analysis of variance (ANOVA).  P values <0.05 were considered statistically significant.
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RESULTS 
 B. abortus S19Δ luxR::kan is more attenuated for survival in macrophages 
and in mice than its parental strain. To determine the role of the deletion of the  luxR 
gene in virulence in S19, J774A.1 macrophages were infected with the marked deletion 
mutant and compared to the parental strain and to the wild-type B. abortus 2308. Using 
an MOI of 100, the ability of the bacteria to enter and survive within this cell line was 
evaluated. One hour post- infection (t=0) there was no difference (p>0.05) between the 
S19 strain or B. abortus 2308 and S19ΔluxR::kan in the number of bacteria infecting the 
cell. By 48 hrs post infection, there was a 0.96 log difference (P<0.005) in the number of 
organisms infecting the cell for S19 vs wild-type 2308 or 1.47 logs difference between 
S19ΔluxR::kan and wild- type 2308. When the marked mutant was compared against 
the parental strain there was a 0.51 log reduction in the number of bacteria surviving 
inside the macrophage (P<0.005) (Fig. 25). These results indicate that S19 is not 
capable of replicating in the same degree when the luxR is deleted.  
 To determine the effect of S19ΔluxR::kan in vivo, mice were inoculated 
intraperitoneally with 1x106 CFU/mice of S19ΔluxR::kan or the parental strain S19. 
Compared to S19, colonization of S19ΔluxR::kan in the spleen did not differ (p >0.05) at 
1,3,5 and 7 weeks , only at 9 weeks bacterial colonization was reduced to significant 
(p<0.005) levels compared to S19 (Fig 26). Interestingly, inflammation in the spleen was 
completely abolished in animals that received the S19ΔluxR::kan (Fig 27, 28).  
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FIG. 25. Survival of the B. abortus S19Δ luxR::kan mutant in J774A. 1 
macrophages. Wild-type strain 2308, S19 and the B. abortus S19ΔluxR::kan mutant 
were used to infect J774A.1 macrophages at a multiplicity of infection of 1:100. After 30 
min of incubation followed by 1 hr of treatment with gentamicin, infected macrophages 
were further incubated for 0 or 48h. Treated cells were lysed, serially diluted and plated 
on TSA or TSA/kanamycin plates for CFU determination. Values are the represented as 
the mean of three independent experiments ± SEM. Differences in macrophage 
colonization by S19 and S19ΔluxR::kan are indicated (**P<0.005)
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FIG 26. Kinetics of clearance of B. abortus S19ΔluxR::kan after infection. BALB/c 
mice (n=5/ time point) were infected with 1 x106 CFU/mouse of wild-type 2308 or  
S19ΔluxR::kan. At  1,3,5,7 and 9 weeks post-infection, mice were euthanized and the 
spleens were assessed for bacterial colonization. Values are the means of individual 
mice ± standard error of the mean. Differences in colonization were determined by 
ANOVA comparing the wild-type to the mutant (**P<0.005). The solid line represents 
the limit of detection which is ≥5 CFU. 
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FIG. 27. Spleen weights after B. abortus  S19ΔluxR::kan infection. BALB/c mice 
were infected with 2 x106 CFU/mouse of wild-type 16M or luxR::Tn5. At 1,3,5,7 and 9 
weeks post-infection, mice were euthanized and the spleens were weighed to determine 
the degree of inflammation conferred by the mutant. Results are expressed as the mean 
± standard error of the mean. Differences in weight were determined by ANOVA 
comparing the wild-type to the mutant (*P<0.05) (**P<0.005). 
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FIG. 28. Spleen morphology in BALB/c mice vaccinated with S19Δ luxR::kan. Mice 
were inoculated with 1x105 CFU of either a) B. abortus 2308, b) S19ΔluxR::kan, c) S19, 
control (d) received 100µl of PBS. Animals were euthanized 2 weeks post- inoculation 
and spleens were weighted, harvested and fixed for histology analysis. 
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 Evaluation of histological changes in mice inoculated with S19ΔluxR::kan. 
Due to the significant differences encountered in spleen size between animals 
inoculated with S19ΔluxR::kan and S19 at  2 weeks post- inoculation, spleens from 
mice inoculated with either S19ΔluxR::kan, S19, B. abortus 2308 or PBS were 
evaluated for histological changes associated with the inflammation. The most dramatic 
histologic changes of B. abortus 2308 and S19 but not in  S19ΔluxR::kan inoculated 
individuals were observed in the liver and the spleen (Fig 29 A, B,C,D, E, F). Degree of 
changes ranged from severe to minor inflammatory changes depending on the 
treatment group.  
 In mice inoculated with B. abortus 2308, changes observed in the spleen were 
severe (occupying approximately 50% of the tissue section examined). The lesions 
were characterized by moderate hyperplasia of the marginal zones and lymphoid 
follicles having pale centers. The marginal zones were coalescing between adjacent 
structure and composed primarily of macrophages and fewer variably degenerate 
neutrophils with occasional lymphocytes and plasma cells, which occasionally extended 
inside the lymphoid and surrounded vessels. Extensions from the marginal zones into 
the red pulp and islands of similar cells were found to occupy up to approximately 60% 
of the red pulp. Diffusely, the splenic capsule was taut. Multifocally within lymphoid 
follicles was a small amount of intrahistiocytic and extracellular hyperesinophilic and 
karyorrhectic debris. Additionally the liver was also compromised. Changes in the liver, 
in a random distribution, included inflammatory aggregates composed primarily of 
macrophages with varying amounts of lymphocytes and variably degenerate neutrophils 
with small amount of hypereosinophilic and karyorrhectic. Bordering the inflammatory 
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aggregates were degenerating hepatocytes characterized by cytoplasmic 
hypereosinophilia and karyorrhexis. The inflammatory aggregates ranged from 
approximately 20 microns to 150 microns. Changes in the lung were inconsistent 
ranging from normal histologic appearance in one of the subjects to perivascular and 
peribronchiolar infiltrates of inflammatory cells composed of a small number of 
macrophages with lesser neutrophils and lymphocytes. The kidneys were generally 
unremarkable in all three of the members in the wild-type group (data not shown).  
 Finally, within  the S19ΔluxR::kan inoculated group, the changes observed in the 
spleen were mild compared to the other groups. Changes in the spleen were mild 
enlargement of lymphoid follicles with pale centers containing immature lymphoid cells 
and rare intracellular and extracellular cellular and karyrrhectic debris. The marginal 
zone in these animals was only mildly hyperplastic and is composed of primarily 
histiocytes with lesser plasma cells and fewer lymphocytes and rare neutrophils. Within 
the red pulp, the plasma cell population was moderately elevated. The liver had 
multifocal, random, and scatter aggregates of histiocytes, lymphocytes and rare 
neutrophils that are often only composed of 5 to 10 cells in diameter but in one of the 
members of the group reach up to approximately 40 cells (50microns). The aggregates 
were primarily midzonal. There was no apparent and significant changes observed in 
the lung and the kidney. The epicardial surface of the heart has small aggregates of 
inflammatory cell composed primarily of lymphocytes with lesser histiocytes and 
neutrophils and two of the animals had multifocal aggregates of deeply basophilic, 
granular and amorphous material and a mild increase in fibrous connective tissue.   
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FIG. 29. Histological analysis of spleen (E-H) and liver (A-D) in BALB/c mice inoculated with either S19, 
S19Δ luxR::kan, B.abortus 2308 or PBS (naïve). Notice the enlargement and coalescing of the white pulp, including 
marginal zones, and the formation of secondary lymphoid follicles in the spleen of  mice vaccinated with either S19 (E) or 
2308 (F). There was  minimal enlargement of the marginal zone in mice vaccinated with S19∆luxR (G) or naïve mice (H). 
In the liver, random distribution of inflammatory foci in mice vaccinated with either S19 (A), or 2308 (B) was observed. 
Normal liver appearance was observed in mice inoculated with either S19DluxR::Kan or PBS (C, D) Inset. Foci of 
inflammation are composed primarily of histiocytes. Bar = 100µm, bar = 25µm (inset).Bar = 200µm.   
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FIG. 29 (continued) 
 
 
C. 
D. 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 29 (continued) 
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FIG. 29 (continued) 
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 Evaluation of immune protection provided by S19ΔluxR::kan.  In order to 
determine the efficacy of the S19ΔluxR::kan mutant as a vaccine, the level of protection 
provided by equal numbers of either S19ΔluxR::kan or S19 was evaluated against B. 
abortus wild-type challenge at 20 weeks post- vaccination. To try to enhance the 
efficacy of the S19ΔluxR::kan mutant, the strain was also encapsulated into alginate 
VpB microbeads at the same dose. At 21 weeks post- vaccination (one week after 
challenge), mice vaccinated with the S19ΔluxR::kan had statistically significant 
decrease in bacterial load in the spleen relative to naïve mice with a 3.06 log (p <0.005) 
reduction for the mutant  and a 5.01 log (p <0.005) reduction for S19. Interestingly when 
the mutant was given in a microencapsulated format, the efficacy of the vaccine was 
increased by 0.75 logs (p < 0.005) compared to the nonencapsulated S19ΔluxR::kan 
vaccinated mice (Fig 30). By encapsulating the organism, the S19ΔluxR::kan vaccine 
efficacy was enhanced to a level that S19 and S19ΔluxR::kan were not statistically 
significant between each other (P>0.15). Importantly, safety in immunization was 
increased in mice vaccinated with the mutant strain, as these mice did not exhibit  the  
splenomegaly that the S19 vaccine caused in these animals (P<0.005) (Fig 31). 
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 FIG. 30. Immunization efficacy of B. abortus S19ΔluxR::kan vaccine formulations. 
BALB/c mice were immunized i.p.  with 1x 105  of either nonencapsulated B abortus 
S19ΔluxR::kan or encapsulated B. abortus S19ΔluxR::kan. Control groups received 
empty capsules or S19 . After 20 weeks, mice were challenged i.p.  with 1 x 105  CFU 
wild-type 2308. One week post challenge, mice were euthanized, spleens harvested 
and the bacterial load was determined. Values are reported as the mean log10 recovery 
of 2308 from spleens. Differences in colonization between the vaccinated  
groups and naïve mice was determined by ANOVA (**P<0.005). Differences between 
encapsulated and nonencapsulated vaccine was determined by ANOVA (# P<0.005). 
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 FIG. 31. Spleen weights after B. abortus wild-type challenge in animals 
previously vaccinated with S19Δ luxR::kan. BALB/c mice were vaccinated with 1x105 
CFU/mouse of S19, encapsulated S19ΔluxR::kan or nonencapsulated S19ΔluxR::kan. 
At 20 weeks post-vaccination, mice were challenged with 1x105 CFU/mouse of wild-type 
2308. One week post- challenge, mice were  euthanized and the spleens were weighed 
to determine the degree of inflammation conferred by the infection. Results are 
expressed as the mean ± standard error of the mean. Differences in weight were 
determined by ANOVA comparing the S19 vaccine strain with the mutant (**P<0.005). 
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 Encapsulated S19ΔluxR::kan elicited stronger humoral responses than 
the nonencapsulated vaccine.  Serum collected at 0,3, 7 and 21 weeks post-
vaccination (1 week post-challenge) was assayed for the presence of Brucella-specific 
IgG1 vs IgG2a antibodies by ELISA. Immunization with encapsulated S19ΔluxR::kan 
elicited stronger IgG1 and IgG2a (1:1 ratio) responses that the nonencapsulated mutant 
(p <0.005) (Fig. 32,33). A higher IgG1 induction was seen throughout the course 
(p>0.05).  In this case, an induction of higher and sustained antibody levels coincides 
with increased protection of encapsulated S19ΔluxR::kan. One week post-challenge, 
animals vaccinated with the mutant elicited a stronger IgG1 responses (2.36: 1 ratio). 
Further studies to correlate IgG isotype and cytokine profile needs to be conducted.   
 S19Δ luxR::kan  mutant failed to induce proinflammatory cytokines. To 
correlate the mild inflammatory response observed in mice vaccinated with the 
S19ΔluxR::kan mutant with cytokine expression in vivo, animals were bled at 0,3,7 and 
21 weeks post vaccination (1 week post-challenge). Animals receiving the mutant by 
either formulation  failed to induce TNFα at any timepoint (Fig. 34), consistently with the 
lack of inflammation seen in this animals by histopathology.  
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FIG 32. IgG1 anti-Brucella antibodies in serum from mice immunized with 
S19Δ luxR::kan. BALB/c mice were inoculated IP with 1x 105  CFU of either 
nonencapsulated S19ΔluxR::kan or encapsulated S19ΔluxR::kan. Control group 
received empty capsules. At 0,3,7 and 21 weeks post vaccination (1 week post-
challenge), serum samples were collected and used for IgG1 determination by ELISA. 
Results are shown as the mean ± standard deviations of absorbance at  A450. 
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FIG 33. IgG2a anti-Brucella antibodies in serum from mice immunized with 
S19Δ luxR::kan. BALB/c mice were inoculated IP with 1x 105  CFU of either 
nonencapsulated S19ΔluxR::kan or encapsulated S19ΔluxR::kan. Control group 
received empty capsules. At 0,3,7 and 21 weeks post vaccination (1 week post-
challenge), serum samples were collected and used for IgG1 determination by ELISA. 
Results are shown as the mean ± standard deviations of absorbance at  A450
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FIG 34. TNFα  production in BALB/c mice immunized with S19ΔluxR::kan. Mice 
were vaccinated with 1 x 105 CFU of either nonencapsulated B. abortus S19ΔluxR::kan, 
encapsulated B. abortus S19ΔluxR::kan. Control group received empty capsules. Mice 
were bled at 0,3,7  weeks post-vaccination and 1  week post-challenge and TNFα 
determination from the serum was performed by ELISA. Results are represented as the 
mean cytokine concentration ± SDEV for each group of five mice.  The significance of 
differences between nonencapsulated and encapsulated formulations at each timepoint 
was determined by ANOVA (**P<0.005). 
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DISCUSSION 
 The development of vaccines to control brucellosis has proven to be a challenge 
for years. Extensive use of S19 vaccine has played an enormous role in reducing  the 
disease in cattle but, it became clear that this vaccine in its existing form is of limited 
use in controlling the disease  in humans and in wildlife populations (15). Years of 
investigations has lead to a better understanding of Brucella virulence and the 
correlates of protective immunity, so that vaccines superior to S19 can be developed. 
The observation that the highest levels of protection are obtained when the host is 
immunized with live vaccines, indicates that persistence and vaccine viability are key 
aspects required for an efficacious anti-brucellosis vaccine (37, 82).  
 Previous studies in our lab, have identified genes related to survival and 
virulence using transposon-based mutagenesis strategies. Among the genes identified, 
B. melitensis luxR mutants have been evaluated for survival in macrophages and the 
mouse model to confirm attenuation and immune potential. We have previously 
demonstrated that B. melitensis luxR mutants are suitable vaccine candidates due to 
their ability to generate protection in BALB/c mice. Also, by using this mutant we were 
able to increase safety by preventing splenomegaly in inoculated mice. Currently 
available vaccine strains S19 and Rev-1 induce splenomegaly in mice (67).  In this 
study, we generated a marked deletion mutant in the S19 vaccine strain with the aim of 
increasing safety and possible use of this vaccine in other populations.  
 S19ΔluxR::kan mutant  was evaluated for survival and attenuation in the 
macrophage and mouse model. As shown in this study, S19ΔluxR::kan was defective 
for survival in macrophages and cleared faster in BALB/c mice. In mice, during the initial 
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weeks post inoculation, the mutant and the parental strain did not elicit significant 
differences but S19ΔluxR::kan was completely cleared from the spleen of mice by 9 
weeks.  In contrast S19 inoculated mice, had   1.36 logs of recoverable bacterial by 9 
weeks. S19ΔluxR::kan safety was further revealed by the lack of splenomegaly in 
inoculated mice. Even at the initial weeks post inoculation (1,3 and 5 ) when the 
bacterial load in the spleen was similar, the mean spleen weights in S19ΔluxR::kan was 
137mgs vs. 172mg at 1 week,  144mgs vs. 322 mgs at 2 weeks and 106mgs vs. 272 
mgs at 3 weeks for S19ΔluxR::kan or S19 respectively.  Histological analysis supported 
this finding by indicating that animals that receive the S19ΔluxR::kan mutant did not 
elicit the degree of inflammatory response observed in S19 vaccinates. Furthermore, 
inflammatory changes observed in other organs including  the liver was totally abolished 
with the mutant. In accordance with this results, the proinflammatory cytokine TNFα 
could not be detected in animals vaccinated with the mutant.  This difference in 
inflammatory response exhibited by S19ΔluxR::kan provide an opportunity to evaluate 
its use as an improved vaccine candidate. 
 In vitro studies using antigen presenting cells have demonstrated that 
microencapsulated antigens are taken up and processed differently as compared to 
nonencapsualted materials (26). Similarly, in vivo data has shown that 
microencapsulation serves to modify the uptake, trafficking and processing of antigens 
(69). Additionally, recent reports demonstrate that persistence of the vaccine strain in 
the host is needed for the development of a suitable and long term immunity (37). 
Consistent with this, S19 vaccine exhibit only modest attenuation, meaning they survive 
longer in the host and produce the unwanted side effects such as the severe 
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inflammation reported here (fig 28). To try to enhance immunization efficacy, we 
investigated the vaccine potential of S19ΔluxR::kan when delivered in a controlled 
release vehicle. For this purpose, alginate a polysaccharide extracted from algae was 
used in  combination with the protein vitelline protein B (VpB) derived from the parasite 
Fasciola hepatica as the capsular material used to entrap the S19ΔluxR::kan mutant 
(61, 73, 75).  By encapsulating the organism we wanted to create the means of 
increased persistence (similar to the S19) but without causing the inflammation 
observed with this vaccine.  
 Protection studies against wild-type challenge with either S19 or S19ΔluxR::kan 
strains protected mice significantly, but the efficacy of the vaccine was reduced in the 
S19ΔluxR::kan mutant. This indicated that the luxR gene in S19 is necessary to induce 
a complete immunity towards Brucella infections. The reduced efficacy was successfully 
compensated by delivering the mutant vaccine in a sustained, microencapsulated 
format. Corroborating the observation of persistence as a function of vaccine efficacy. 
Encapsulation of live attenuated organisms is an interesting approach to improve 
immunization efficacy in potential vaccine candidates. It is important to mention that the 
viability of the bacteria was not compromised due to the mild conditions exposed during 
this procedure.  
 The degree of protection was conferred by either the encapsulated or 
nonencapsulated S19ΔluxR::kan mutants was compared to humoral profiles. 
Immunization with encapsulated S19ΔluxR::kan induced higher IgG1 and IgG2a levels 
compared to the nonencapsulated S19ΔluxR::kan mutant. Contrary to what was 
expected, 1 week post-challenge, animals that received the encapsulated vaccine, 
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mounted a stronger IgG1 response. Further investigations to determine the cytokine 
profiles elicited by these mice needs to be conducted to explain this finding.   
 A luxR knockout was created in the S19 vaccine and investigated for its potential 
use as an improved vaccine candidate.  Vaccination with a sustained release vehicle to 
enhance vaccination efficacy was evaluated utilizing the live S19∆luxR in encapsulated 
alginate microspheres containing a non-immunogenic eggshell precursor protein of the 
parasite Fasciola hepatica (Vitelline protein B, VpB). BALB/c mice were immunized 
intraperitoneally with either encapsulated or unencapsulated S19ΔluxR at a dose of 
1x105 CFU per animal to evaluate immunogenicity, safety, and protective efficacy. 
Humoral responses post-vaccination indicate that the vaccine candidate was able to 
elicit an anti-Brucella specific IgG response even when the vaccine was administered in 
an encapsulated format. Safety was revealed by the absence of splenomegaly in mice 
that were inoculated with the mutant. Finally, a single dose with the encapsulated 
mutant conferred higher levels of protection compared to the unencapsulated vaccine. 
These results suggest that S19ΔluxR is safer than S19, induces protection in mice, and 
should be considered as a vaccine candidate when administered in a sustained release 
manner. 
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SUMMARY AND CONCLUSION 
 
 Brucellosis is an important zoonotic disease of nearly worldwide distribution.  
The occurrence of the infection in humans is largely dependent on the prevalence of 
brucellosis in animal reservoirs, including wildlife.  The current vaccine strains used for 
cattle, S19 and RB51 have proven ineffective in protecting humans and wildlife 
populations including  bison (Bison bison) and elk (Cervus nelsoni) from infection and 
abortion.  To test possible improvements in vaccine efficacy, a novel approach of 
immunization was examined using alginate microspheres containing a non-
immunogenic eggshell precursor protein of the parasite Fasciola hepatica (vitelline 
protein B, VpB) to deliver new live vaccine candidates.  
 Brucella species defective in the luxR gene, were identified as attenuated in 
macrophages and mice, and were chosen as targets to create vaccine strains. This 
gene is involved in known virulence mechanisms of the type IV secretion system. 
Additionally current vaccine strains were  re-evaluated in Red Deer. 
 In the mouse model, the luxR::Tn5  B. melitensis  and S19ΔluxR::Km mutants 
proved to be suitable vaccine candidates based on  its reduced virulence in 
macrophages and in BALB/c mice and ability to generate protection in the mouse 
model. We were able to demonstrate an improvement in the efficacy of the vaccine 
when the immunogen  was given using a controlled release vehicle. In the case of 
luxR::Tn5 vaccinates, encapsulated immunized mice produced higher concentrations of 
circulating interleukin 12 (IL12) and gamma interferon (IFNγ), suggesting an induction of 
a Th1 response. 
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 The deer model was necessary to assess the use of encapsulation in target 
species that are naturally infected with Brucella. Due to the fact that current vaccine 
strains do not confer a good protection against infection in  Red Deer, a different 
methodology of vaccination using microencapsulation was investigated. The efficacy of 
both S19 and RB51 was enhanced when the vaccine was given in a sustained release 
format. Together, these results suggest that microencapsulation of live Brucella 
produces an enhanced delivery vaccine system against brucellosis increasing the 
efficacy of poorly-performing nonencapsulated vaccine candidates.  
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